Allosteric EGFR inhibitors and their use
Allosteric EGFR inhibitors address the limitations of current TKIs by targeting mutant EGFR through alternative mechanisms, enhancing efficacy and reducing toxicity in NSCLC treatment.
Patent Information
- Application Number
- JP2025137144
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-11-09
- Filing Date
- 2025-08-20
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-06-09
AI Technical Summary
Current EGFR tyrosine kinase inhibitors (TKIs) face limitations in treating EGFR mutant NSCLC due to secondary mutations like T790M and C797S, leading to resistance and toxicity, with no suitable compounds targeting mutant EGFR through alternative mechanisms.
Development of allosteric EGFR inhibitors, represented by compounds of Formula I, which target sites other than the ATP binding site to inhibit EGFR, including specific substitutions and functional groups that enhance potency and selectivity.
These allosteric inhibitors effectively target mutant EGFR, potentially overcoming resistance and reducing toxicity, offering a new mechanism for treating EGFR mutant NSCLC.
Smart Images

Figure 0007949121000001 
Figure 0007949121000002 
Figure 0007949121000003
Abstract
Description
[Technical Field]
[0001] Related applications This application claims priority to U.S. Provisional Application No. 63 / 036,622, filed on 9 June 2020, and U.S. Provisional Application No. 63 / 111,429, filed on 9 November 2020, the entire contents of which are incorporated herein by reference.
[0002] Statement regarding federally supported research or development. This invention was made with government support under grant number R01 CA201049 granted by the National Institutes of Health (NIH). The government has certain rights in this invention. [Background technology]
[0003] The epidermal growth factor receptor (EGFR, Erb-B1) belongs to a family of receptor tyrosine kinases that mediate the proliferation, differentiation, and survival of normal and malignant cells (Arteaga, CL, J. Clin. Oncol. 19, 2001, 32-40). EGFR dysregulation is associated with many types of human cancer, and is accompanied by overexpression of the receptor, which is present in at least 70% of human cancers (Seymour, LK, Curr. Drug Targets 2, 2001, 117-133), including non-small cell lung cancer, breast cancer, glioma, squamous cell carcinoma of the head and neck, and prostate cancer (Raymond, E., et al., Drugs 60 (Suppl. 1), 2000, 15-23, discussion 41-2; Salomon, DS, et al., Crit. Rev. Oncol. Hematol. 19, 1995, 183-232; Voldborg, BR, et al., Ann. Oncol. 8, 1997, 1197-1206). Therefore, EGFR has emerged as an attractive target for the design and development of diagnostic and therapeutic agents that can specifically bind to and inhibit the tyrosine kinase activity and signaling pathways of its receptor in cancer cells. For example, the EGFR tyrosine kinase (EGFR-TK) reversible inhibitor TARCEVA® is approved by the FDA for the treatment of NSCLC and advanced pancreatic cancer. Other anti-EGFR target molecules, including lapatinib and IRESSA®, are also approved.
[0004] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are an effective clinical therapy for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) (Mok, TS, et al., N.Engl. J. Med. 361, 2009, 947-57; Paez, JG, et al., Science 304, 2004, 1497-500; Lynch, TJ, et al., N.Engl. J. Med. 350, 2004, 2129-39; Rosell, R., et al., Lancet Oncol. 13, 2012, 239-46). Several randomized clinical trials have demonstrated that EGFR TKIs are more effective than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC, as measured by response rate (RR) and progression-free survival (PFS) (Mok, TS, et al., N.Engl. J.Med. 361, 2009, 947-57; Rosell, R., et al., Lancet Oncol. 13, 2012, 239-46; Sequest, L., et al., J.Clin. Oncol. 31, 2013, 3327-34; Wu, Y.L, et al., Lancet Oncol. 15, 2014, 213-22; Maemondo, M., et al., N.Engl. J.Med. 362, 2010, 2380-8; Zhou, C., et al., Lancet (Oncol.12,2011,735-42, Mitsudomi,T.,et al.,Lancet Oncol.11,2010,121-8). However, the majority of patients will experience disease progression after successful treatment with EGFR TKIs. The most common mechanism of acquired resistance, detected in 60% of patients, is a secondary mutation in EGFR at position T790 (T790M) (Yu,HA,et al.,Clin.Cancer Res.19,2013,2240-7). This mutation results in increased ATP affinity, making it more difficult for the reversible EGFR TKIs gefitinib and erlotinib to bind to the EGFR TKI domain (Yun CH,et al.,Proc.Natl.Acad.Sci.USA 105,2008,2070-5).
[0005] Covalent EGFR inhibitors have emerged to inhibit EGFR T790M-containing cancers. However, in lung cancer patients, afatinib is only effective in EGFR TKI-naive EGFR mutant cancers and has a less than 10% response rate (RR) in patients with NSCLC that have developed resistance to gefitinib or erlotinib (Miller, VA, et al., Lancet Oncol. 13, 2012, 528-38). Afatinib is a potent inhibitor of both mutant and wild-type (WT) EGFR. Inhibition of WT EGFR results in toxicity, including skin rash and diarrhea, which limits the ability to escalate the afatinib dose in patients to what is necessary to inhibit EGFR T790M. Irreversible pyrimidine EGFR inhibitors, including the tool compound WZ4002 and the clinical compounds CO-1686 and AZD9291, have overcome many of the limitations of afatinib (Zhou, W., et al., Nature 462, 2009, 1070-4; Walter, AO, et al., Cancer Discov. 3, 2013, 1404-15; Cross, DAE, et al., Cancer Discov. 4, 2014, 1046-61). They are not only more potent against EGFR T790M but also selectively inhibit variants more than WT EGFR, which should result in increased clinical efficacy and lower toxicity compared to afatinib (Zhou, W., et al., Walter AO, et al., Cross, DAE, et al.).
[0006] However, all current EGFR TKIs target the ATP site, and third-generation irreversible inhibitors can overcome T790M, but they are all neutralized by the C797S mutation already present in treated patients. Cetuximab, an anti-EGFR antibody that inhibits receptor dimerization, is ineffective in EGFR mutant NSCLC because the mutant activation of the kinase is actually "downstream" of receptor dimerization.
[0007] Currently, no suitable compounds with an alternative mechanism of action targeting mutant EGFR are available. Therefore, there is a need for potent small molecule EGFR inhibitors with an alternative mechanism of action targeting mutant EGFR. [Overview of the Initiative]
[0008] In one embodiment, in this specification, Formula I: [ka] Or a pharmaceutically acceptable salt thereof is provided. During the ceremony, [ka] This represents any double bond, A and A' are, independently, CH and CR. 8 , or N, W is either N or C. Z is selected from the group consisting of S, O, N, NH, N-Me, CH2, CH, C-halo, C-(C1-C3 alkyl), or C-(C1-C3 alkoxy). X and Y are independently S, O, N, CH, NR 3 , or CR 3 And, However, at least one of X, Y, or Z is CH. R 1 C(O)NHR 9 Selected from the group consisting of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, where aryls, heteroaryls, cycloalkyls, and heterocycloalkyls have 1, 2, or 3 R 8 It is arbitrarily replaced with, R 2 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 6 It is arbitrarily replaced with, R3 is, independently at each occurrence, halogen, OR 4 , NR 4 R 4 , SO2R 4 , SO2NHR 4 , NHSO2R 4 , C(O)OR 4 , C(O)NHR 4 , NHC(O)R 4 , C(O)R 4 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 3-7 membered cycloalkyl, C4-C7 cycloalkenyl, C6-C 10 aryl, 5-6 membered heteroaryl, and 5-7 membered heterocyclyl, wherein the alkyl, alkenyl, or alkynyl is each optionally substituted 1, 2, or 3 times with R 4 , and the aryl, heteroaryl, or heterocyclyl is each optionally substituted 1, 2, or 3 times with R 5 , R 4 is, independently at each occurrence, selected from the group consisting of H, C1-C6 alkyl, (CH2) 0~3 -(C3-C7 cycloalkyl), (CH2) 0~3 -(C4-C7 cycloalkenyl), (CH2) 0~3 -(C6-C 10 aryl), (CH2) 0~3 -(5-6 membered heteroaryl), and (CH2) 0~3 -(5-7 membered heterocyclyl), wherein the aryl, heteroaryl, or heterocyclyl is each optionally substituted 1, 2, or 3 times with R 5 , R 5 is, independently at each occurrence, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkylamine, 3-10 membered cycloalkyl, halogen, COOH, C(O)O(C1-C6 alkyl), O(CH2) 1~3 -OH, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, OH, CN, (CH2) 0~3 -(C6-C 10(Ayl), (CH2) 0~3 -(5-6 member heteroaryl), and (CH2) 0~3 -Selected from the group consisting of (5-7 member heterocyclils), and aryl, heteroaryl, or heterocyclil can be any of the following: 7 It is replaced once, twice, or three times. Alternatively, two R's 5 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls, all of which can optionally be R 7 It can be substituted once, twice, or three times. R 6 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, Alternatively, two R's 6 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 7 These are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, SO2NH2, SO2NH(C1-C6 alkyl), SO2N(C1-C6 alkyl)2, (CH2) 1~2 -OH, C(O)(CH2) 1~2 A substituent selected from the group consisting of -OH, C(O)(C1~C6alkyl), and C(O)O(C1~C6alkyl), Alternatively, two R's 7These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 8 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, 3-6 member cycloalkyl, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, R 9 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 8 It can be arbitrarily replaced with.
[0009] In another embodiment, the Specified Pharmaceutical Composition is provided, comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
[0010] In yet another embodiment, this specification provides a method for treating cancer in a subject in need of cancer treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula I.
[0011] In another embodiment, the Specified provides a method for inhibiting a kinase in a subject requiring kinase inhibition, comprising administering a therapeutically effective amount of a compound of formula I to the subject.
[0012] In one embodiment, a method is provided herein for treating or preventing a kinase-mediated disorder in a subject requiring treatment or prevention of such disorder, comprising administering to the subject a therapeutically effective amount of a compound of formula I. [Modes for carrying out the invention]
[0013] definition The following are definitions of various terms used to describe the compounds and compositions disclosed herein. These definitions apply to the terms used throughout this specification and the claims unless they are limited in specific cases individually or as part of a larger group.
[0014] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art. Generally, the nomenclature used herein, as well as the experimental procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry, are well known and commonly used in the art.
[0015] As used herein, the articles "a" and "an" refer to one or more (i.e., at least one) grammatical objects of such articles. For example, "element" means one or more elements. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is not limited to these.
[0016] The term “approximately” as used herein will be understood by those skilled in the art and will vary to some extent in the context in which it is used. When referring to measurable values such as quantities or lengths of time, the term “approximately” as used herein encompasses variations of ±20% or ±10%, for example, ±5%, ±1%, and ±0.1%, from a specified value, as such variations are appropriate for carrying out the disclosed method.
[0017] As used herein, terms such as “administration” refer to providing a therapeutic agent. Multiple techniques for administering therapeutic agents exist in the art, including, but not limited to, intravenous, oral, aerosol, parenteral, intraocular, intrapulmonary, and topical administration.
[0018] The terms “treat,” “be treated,” “treating,” or “treatment” include the reduction or mitigation of at least one symptom associated with or caused by the condition, disorder, or disease being treated. In certain embodiments, treatment for a cancer-related condition includes contacting wild-type or mutant EGFR with an effective amount of a compound disclosed herein.
[0019] As used herein, the terms “prevent” or “prevention” mean the absence of a disability or disease if no disability or disease already exists, or the absence of further disability or disease if an disability or disease has already occurred. The ability to prevent some or all of the symptoms associated with the disability or disease is also considered.
[0020] As used herein, the terms “patient,” “individual,” or “subject” refer to human or non-human mammals. Examples of non-human mammals include livestock and pets, such as sheep, cattle, pigs, dogs, cats, and marine mammals. Preferably, the patient, subject, or individual is human.
[0021] As used herein, the terms “effective dose,” “pharmaceutical effective dose,” and “therapeutic effective dose” refer to a non-toxic amount of a drug sufficient to produce a desired biological outcome. This outcome may be a reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired change in the biological system. The appropriate therapeutic dose in any individual case can be determined by those skilled in the art using conventional experimentation.
[0022] As used herein, the term “pharmaceutically acceptable” means a substance, such as a carrier or diluent, that can be administered to an individual without inactivating the biological activity or properties of a compound, and which is relatively non-toxic, that is, a substance that can be administered to an individual without causing undesirable biological effects or interacting in a harmful manner with any of the components of the composition in which it is contained.
[0023] As used herein, “pharmaceutically acceptable salt” refers to a derivative of a disclosed compound, wherein the parent compound is modified by converting the present acidic or base moiety into a salt form. Examples of pharmaceutically acceptable salts, but not limited to, include inorganic or organic acidic salts of basic residues such as amines, and alkali or organic salts of acidic residues such as carboxylic acids. Examples of pharmaceutically acceptable salts in this disclosure include conventional non-toxic salts of parent compounds formed from non-toxic inorganic or organic acids. Pharmaceutically acceptable salts in this disclosure can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods. Generally, such salts can be prepared by reacting the free acidic or base form of these compounds with a stoichiometric amount of a suitable base or acid in water, an organic solvent, or a mixture of the two, generally in non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile. The term “pharmaceutically acceptable salt” is not limited to monosalts, i.e., 1:1 salts. For example, "pharmaceutically acceptable salts" include bis-salts such as bis-hydrochloride. Lists of suitable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
[0024] As used herein, the term “prodrug” refers to a precursor compound that will undergo metabolic activation in vivo to produce an active drug. Therefore, for example, a prodrug of a compound provided herein will undergo metabolic activation to produce the compound when administered to a subject.
[0025] As used herein, the terms “composition” or “pharmaceutical composition” refer to a mixture of at least one useful compound in this disclosure and a pharmaceutically acceptable carrier. Pharmaceutical compositions facilitate the administration of a compound to a patient or subject. Multiple methods exist in the art for administering compounds, including, but not limited to, intravenous, oral, aerosol, parenteral, intraocular, intrapulmonary, and topical administration.
[0026] As used herein, the term “pharmaceutical combination” means a product obtained from a mixture or combination of two or more active ingredients, and includes both immobilized and unimmobilized combinations of active ingredients. The term “immobilized combination” means that both the active ingredients, e.g., the compounds and adjuvants of this disclosure, are administered to the patient simultaneously in the form of a single entity or dosage. The term “unimmobilized combination” means that both the active ingredients, e.g., the compounds and adjuvants of this disclosure, are administered to the patient simultaneously, in parallel, or sequentially as separate entities without any specific time constraints, and such administration provides therapeutically effective levels of the two compounds in the patient’s body. The latter also applies to cocktail therapies, e.g., the administration of three or more active ingredients.
[0027] As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspension, diluent, excipient, thickener, solvent, or encapsulation material, that is involved in carrying or transporting a useful compound in this disclosure into or to a patient in order to perform its intended function. Generally, such constructs are carried or transported from one organ or part of the body to another. Each carrier must be “acceptable” in the sense that it is compatible with the other components of the formulation, including the useful compound in this disclosure, and is not harmful to the patient. Some examples of substances that can serve as pharmaceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogenic substance removal water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer; and other non-toxic, suitable materials used in pharmaceutical formulations.
[0028] As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antimicrobial and antifungal agents, and absorption retarders, etc., that are active and compatible with the useful compounds in this disclosure and are physiologically acceptable to the patient. Auxiliary active compounds may also be added to the composition. “pharmaceutically acceptable carrier” may further include pharmaceutically acceptable salts of the compounds disclosed herein. Other further components that may be included in a pharmaceutical composition are well known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
[0029] As used herein, the term "EGFR" refers to the epidermal growth factor receptor (or referred to as ErbB-1 or HER1), and may refer to the wild-type receptor or a receptor containing one or more mutations.
[0030] As used herein, the terms "HER" or "Her" refer to members of the ErbB receptor tyrosine kinase family, including EGFR, ERBB2, HER3, and HER4.
[0031] As used herein, the term “allosteric site” refers to a site on EGFR other than the ATP binding site, for example, a site characterized in the crystal structure of EGFR. An “allosteric site” may be a site close to the ATP binding site, for example, a site characterized in the crystal structure of EGFR. For example, an allosteric site may contain one or more of the following amino acid residues of the epidermal growth factor receptor (EGFR): Lys745, Leu788, Ala743, Cys755, Leu777, Phe856, Asp855, Met766, Ile759, Glu762, and / or Ala763.
[0032] As used herein, the term “EGFR dimerization inhibitor,” or its iteration, refers to an inhibitor of dimerization in which the C lobe of the “activator” subunit acts on the N lobe of the “receptor” subunit. Examples of EGFR dimerization inhibitors include, but are not limited to, cetuximab, trastuzumab, panitumumab, and Mig6.
[0033] As used herein, the term “alkyl” means a linear or branched hydrocarbon having a specified number of carbon atoms, either by itself or as part of another substituent, unless otherwise specified (i.e., C1-C6 alkyl means an alkyl having 1 to 6 carbon atoms), and includes linear and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, and hexyl. Other examples of C1-C6 alkyl include ethyl, methyl, isopropyl, isobutyl, n-pentyl, and n-hexyl.
[0034] As used herein, the term "haloalkyl" refers to an alkyl group as defined above, substituted with one or more halo substituents, where alkyl and halo are as defined herein. Haloalkyls include, for example, chloromethyl, trifluoromethyl, bromoethyl, and chlorofluoroethyl.
[0035] As used herein, the term "alkoxy" refers to an -O-alkyl group, where alkyl is as defined herein. Examples of alkoxys include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, and t-butoxy.
[0036] As used herein, the term "alkylamine" refers to an -NH-alkyl group, where alkyl is as defined herein. Examples of alkylamines include methylamine, ethylamine, isopropylamine, n-propylamine, n-butylamine, sec-butylamine, and t-butylamine.
[0037] As used herein, the term "haloalkoxy" refers to an -O-haloalkyl group, where a haloalkyl group is as defined herein. Haloalkoxy groups include, for example, chloromethoxy, trifluoromethoxy, bromoethoxy, and chlorofluoroethoxy.
[0038] As used herein, the term “alkenyl” refers, in certain embodiments, to a monovalent group derived from a hydrocarbon moiety containing 2 to 6 or 2 to 8 carbon atoms having at least one carbon-carbon double bond. The alkenyl group may or may not be a bond site to another group. The term “alkenyl” includes, but is not limited to, ethenyl, 1-propenyl, 1-butenyl, heptenyl, octenyl, and the like.
[0039] As used herein, the term “alkynyl” refers, in certain embodiments, to a monovalent group derived from a hydrocarbon moiety containing 2 to 6 or 2 to 8 carbon atoms having at least one carbon-carbon triple bond. The alkynyl group may or may not be a bond site to another group. The term “alkynyl” includes, but is not limited to, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and others.
[0040] As used herein, the terms “halo” or “halogen” mean, unless otherwise specified, a fluorine, chlorine, bromine, or iodine atom, preferably fluorine, chlorine, or bromine, more preferably fluorine or chlorine, either alone or as part of another substituent.
[0041] As used herein, the term “cycloalkyl” means a fully saturated non-aromatic carbocyclic system having one, two, or three rings, such rings may be condensed. The term “condensed” means that a second ring is present (i.e., bonded or formed) by having two adjacent atoms common (i.e., shared) with the first ring. Cycloalkyl also includes bicyclic structures that may be essentially bridged or spirocyclic, in which each individual ring in the bicyclic structure has a range of 3 to 8 atoms. The term “cycloalkyl” includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[3.1.0]hexyl, spiro[3.3]heptanyl, and bicyclo[1.1.1]pentyl.
[0042] As used herein, the term "cycloalkenyl" means a partially saturated non-aromatic carbon ring system having one, two, or three rings, wherein such rings may be condensed, and at least one ring is sp 2 Contains carbon-carbon bonds. The term "cycloalkenyl" includes, but is not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, bicyclo[3.1.0]hexenyl, spiro[3.3]-heptanenyl, and bicyclo[1.1.1]pentenyl.
[0043] As used herein, the term “heterocyclyl” means a non-aromatic carbocyclic system having 1, 2, 3, or 3 rings, containing 1, 2, or 4 heteroatoms independently selected from N, O, and S, such rings may be condensed, and condensation is defined above. Heterocyclyls also include bicyclic structures that can be essentially bridged or spirocyclic, in which each individual ring within the two rings varies with 3 to 8 atoms and contains 0, 1, or 2 N, O, or S atoms. The term "heterocyclyl" includes, but is not limited to, cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams), but specifically includes epoxyzyl, oxetanyl, tetrahydrofuranil, tetrahydropyranil (i.e., oxanil), pyranyl, dioxanil, azilidinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinanyl, 1,3-thiadinyl, 2-azabicyclo[2.1.1]hexanyl, 5-azabicyclo[2.1.1]hexanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.1] Butanyl, 2-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azabicyclo-[3.1.0]hexanyl, 3-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 3-oxa-7-azabicyclo[3.3.1]-nonanyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, 2-oxa-5- This includes azabicyclo[2.2.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2-oxaspiro-[3.3]heptanyl, 2-oxaspiro[3.5]nonanyl, 3-oxaspiro[5.3]nonanyl, and 8-oxabicyclo[3.2.1]octanyl.
[0044] As used herein, the term "aromatic" refers to a carbocyclic or heterocyclic ring comprising one or more polyunsaturated rings and possessing aromatic characteristics (i.e., having (4n+2) delocalized π (pi) electrons (where n is an integer)).
[0045] As used herein, the term “aryl” means an aromatic carbocyclic system comprising one, two, or three rings, which may be condensed (condensation as defined above). If the rings are condensed, one of the rings must be completely unsaturated, and the condensed ring(s) may be completely saturated, partially unsaturated, or completely unsaturated. The term “aryl” includes, but is not limited to, phenyl, naphthyl, indanyl, and 1,2,3,4-tetrahydronaphthalenyl. In some embodiments, the aryl group has six carbon atoms. In some embodiments, the aryl group has six to ten carbon atoms. In some embodiments, the aryl group has six to sixteen carbon atoms.
[0046] As used herein, the term “heteroaryl” means an aromatic carbocyclic system having one, two, three or four heteroatoms independently selected from N, O, and S, and having one, two or three rings which may be condensed (condensation is as defined above). The term “heteroaryl” includes, but is not limited to, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridadinyl, pyrimidinyl, pyrazinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, 5,6,7,8-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 6,7-dihydro-5H-cyclopenta[b]pyridinyl, 6,7-dihydro-5H-cyclopenta [c]pyridinyl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]-triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydro-1H-indazolyl, and 4,5,6,7-tetrahydro-2H-indazolyl.
[0047] It should be understood that if an aryl, heteroaryl, cycloalkyl, or heterocyclyl moiety can be bonded or otherwise linked to a specified moiety via different ring atoms (i.e., indicated or described without specifying a particular bond site), all possible points are assumed, whether via carbon atoms or, for example, trivalent nitrogen atoms. For example, the term "pyridinyl" means 2-, 3-, or 4-pyridinyl, and the term "thienyl" means 2- or 3-thioenyl.
[0048] As used herein, the term "substituted" means that an atom or group of atoms has substituted hydrogen as a substituent bonded to another group.
[0049] As used herein, the term “optionally substituted” means that the referenced group may or may not be substituted. In one embodiment, the referenced group may be substituted with zero substituents, i.e., the referenced group is unsubstituted. In another embodiment, the referenced group may be substituted with one or more further groups selected individually and independently from the groups described herein.
[0050] compound This specification provides compounds that are allosteric inhibitors of epidermal growth factor receptor (EGFR) useful for treating kinase-mediated disorders, including cancer and other proliferative disorders.
[0051] In one embodiment, in this specification, Formula I: [ka] Or a pharmaceutically acceptable salt thereof is provided. During the ceremony, [ka] This represents any double bond, A and A' are, independently, CH and CR. 8 , or N, W is N, C, or CH; Z is selected from the group consisting of S, O, N, NH, N-Me, CH2, CH, C-halo, C-(C1-C3 alkyl), or C-(C1-C3 alkoxy). X and Y are independently S, O, N, CH, NR 3 , or CR 3 And, However, at least one of X, Y, or Z is CH. R 1 C(O)NHR 9Selected from the group consisting of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, where aryls, heteroaryls, cycloalkyls, and heterocycloalkyls have 1, 2, or 3 R 8 It is arbitrarily replaced with, R 2 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 6 It is arbitrarily replaced with, R 3 Each occurrence is independent of halogen, OR 4 , NR 4 R 4 SO2R 4 SO2NHR 4 NHSO2R 4 , C(O)OR 4 C(O)NHR 4 NHC(O)R 4 , C(O)R 4 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 3-7 member cycloalkyl, C4-C7 cycloalkenyl, C6-C 10 Selected from the group consisting of aryls, 5-6 membered heteroaryls, and 5-7 membered heterocyclines, alkyl, alkenyl, or alkynyl are each optionally R 4 The aryl, heteroaryl, or heterocyclyl is substituted once, twice, or three times, and each can be optionally replaced with R 5 It is replaced once, twice, or three times. R 4 In each occurrence, H, C1-C6 alkyl, (CH2) 0~3 -(C3~C7 cycloalkyl), (CH2) 0~3 -(C4~C7 cycloalkenyl), (CH2) 0~3 -(C6~C 10 (Ayl), (CH2) 0~3 -(5-6 member heteroaryl), and (CH2) 0~3-(5- to 7-membered heterocyclyl), wherein aryl, heteroaryl, or heterocyclyl is each optionally substituted with R 5 at 1, 2, or 3 positions, R 5 at each occurrence is independently selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkylamine, 3- to 10-membered cycloalkyl, halogen, COOH, C(O)O(C1-C6 alkyl), O(CH₂) 1~3 -OH, NH₂, NH(C1-C6 alkyl), N(C1-C6 alkyl)₂, OH, CN, (CH₂) 0~3 -(C6-C 10 aryl), (CH₂) 0~3 -(5- to 6-membered heteroaryl), and (CH₂) 0~3 -(5- to 7-membered heterocyclyl), wherein aryl, heteroaryl, or heterocyclyl is each optionally substituted with R 7 at 1, 2, or 3 positions, alternatively, two R 5 together with the atoms to which they are attached can form a 5- to 10-membered heteroaryl, 6- to 10-membered aryl, 3- to 10-membered heterocycloalkyl, or 3- to 10-membered cycloalkyl, all of which are optionally substituted with R 7 at 1, 2, or 3 positions, R 6 at each occurrence is independently selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO₂, NH₂, NH(C1-C6 alkyl), N(C1-C6 alkyl)₂, (CH₂) 1~4 OH, S(O) 0~2 H, S(O) 0~2 NH₂, or CN, alternatively, two R 6 together with the atoms to which they are attached can form a 5- to 10-membered heteroaryl, 6- to 10-membered aryl, 3- to 10-membered heterocycloalkyl, or 3- to 10-membered cycloalkyl, R 7 These are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, SO2NH2, SO2NH(C1-C6 alkyl), SO2N(C1-C6 alkyl)2, (CH2) 1~2 -OH, C(O)(CH2) 1~2 A substituent selected from the group consisting of -OH, C(O)(C1~C6alkyl), and C(O)O(C1~C6alkyl), Alternatively, two R's 7 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 8 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, 3-6 member cycloalkyl, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, R 9 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 8 It can be arbitrarily replaced with.
[0052] In another embodiment, the compound of formula X as used herein: [ka] Or a pharmaceutically acceptable salt thereof is provided. During the ceremony, [ka] This represents any double bond, A and A' are, independently, CH and CR. 8 , or N, Alternatively, A is absent, W is N, C, or CH; Z is selected from the group consisting of S, O, N, NH, N-Me, CH2, CH, C-halo, C-(C1-C3 alkyl), or C-(C1-C3 alkoxy). X and Y are independently S, O, N, CH, NR 3 , or CR 3 And, However, at least one of X, Y, or Z is CH. R 1 C(O)NHR 9 Selected from the group consisting of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, where aryls, heteroaryls, cycloalkyls, and heterocycloalkyls have 1, 2, or 3 R 8 It is arbitrarily replaced with, R 2 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 6 It is arbitrarily replaced with, R 3 Each occurrence is independent of halogen, OR 4 , NR 4 R 4 SO2R 4 SO2NHR 4 NHSO2R 4 , C(O)OR 4 C(O)NHR 4 NHC(O)R 4 , C(O)R 4 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 3-7 member cycloalkyl, C4-C7 cycloalkenyl, C6-C 10Selected from the group consisting of aryls, 5-6 membered heteroaryls, and 5-7 membered heterocyclines, alkyl, alkenyl, or alkynyl are each optionally R 4 The aryl, heteroaryl, or heterocyclyl is substituted once, twice, or three times, and each can be optionally replaced with R 5 It is replaced once, twice, or three times. R 4 In each occurrence, H, C1-C6 alkyl, (CH2) 0~3 -(C3~C7 cycloalkyl), (CH2) 0~3 -(C4~C7 cycloalkenyl), (CH2) 0~3 -(C6~C 10 (Ayl), (CH2) 0~3 -(5-6 member heteroaryl), and (CH2) 0~3 -Selected from the group consisting of (5-7 member heterocyclils), and aryl, heteroaryl, or heterocyclil can be any of the following: 5 It is replaced once, twice, or three times. R 5 These are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkylamine, 3-10 membered cycloalkyl, halogen, COOH, C(O)O(C1-C6 alkyl), O(CH2) 1~3 -OH, NH2, NH(C1~C6 alkyl), N(C1~C6 alkyl)2, OH, CN, (CH2) 0~3 -(C6~C 10 (Ayl), (CH2) 0~3 -(5-6 member heteroaryl), and (CH2) 0~3 -Selected from the group consisting of (5-7 member heterocyclils), and aryl, heteroaryl, or heterocyclil can be any of the following: 7 It is replaced once, twice, or three times. Alternatively, two R's 5 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls, all of which can optionally be R7 It can be substituted once, twice, or three times. R 6 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, Alternatively, two R's 6 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 7 These are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, SO2NH2, SO2NH(C1-C6 alkyl), SO2N(C1-C6 alkyl)2, (CH2) 1~2 -OH, C(O)(CH2) 1~2 A substituent selected from the group consisting of -OH, C(O)(C1~C6alkyl), and C(O)O(C1~C6alkyl), Alternatively, two R's 7 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 8 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, 3-6 member cycloalkyl, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2Selected from the group consisting of NH2 or CN, R 9 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 8 It can be arbitrarily replaced with.
[0053] In one aspect of equation X, A and A' are, independently, CH2 and CHR. 8 , NH, or NR 8 The remaining variables are defined herein.
[0054] In another embodiment, the compound of formula XX as used herein: [ka] Or a pharmaceutically acceptable salt thereof is provided. During the ceremony, A and A' are, independently, CH2 and CHR. 8 , NH, or NR 8 And, Alternatively, A is absent, Z is selected from the group consisting of N, CH, C-halo, C-(C1-C3 alkyl), or C-(C1-C3 alkoxy). X and Y are independently N, CH, or CR. 3 And, However, at least one of X, Y, or Z is CH. R 1 C(O)NHR 9 Selected from the group consisting of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, where aryls, heteroaryls, cycloalkyls, and heterocycloalkyls have 1, 2, or 3 R 8 It is arbitrarily replaced with, R 2The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 6 It is arbitrarily replaced with, R 3 Each occurrence is independent of halogen, OR 4 , NR 4 R 4 SO2R 4 SO2NHR 4 NHSO2R 4 , C(O)OR 4 C(O)NHR 4 NHC(O)R 4 , C(O)R 4 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 3-7 member cycloalkyl, C4-C7 cycloalkenyl, C6-C 10 Selected from the group consisting of aryls, 5-6 membered heteroaryls, and 5-7 membered heterocyclines, alkyl, alkenyl, or alkynyl are each optionally R 4 The aryl, heteroaryl, or heterocyclyl is substituted once, twice, or three times, and each can be optionally replaced with R 5 It is replaced once, twice, or three times. R 4 In each occurrence, H, C1-C6 alkyl, (CH2) 0~3 -(C3~C7 cycloalkyl), (CH2) 0~3 -(C4~C7 cycloalkenyl), (CH2) 0~3 -(C6~C 10 (Ayl), (CH2) 0~3 -(5-6 member heteroaryl), and (CH2) 0~3 -Selected from the group consisting of (5-7 member heterocyclils), and aryl, heteroaryl, or heterocyclil can be any of the following: 5 It is replaced once, twice, or three times. R 5These are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C3 alkylamine, 3-10 membered cycloalkyl, halogen, COOH, C(O)O(C1-C6 alkyl), O(CH2) 1~3 -OH, NH2, NH(C1~C6 alkyl), N(C1~C6 alkyl)2, OH, CN, (CH2) 0~3 -(C6~C 10 (Ayl), (CH2) 0~3 -(5-6 member heteroaryl), and (CH2) 0~3 -Selected from the group consisting of (5-7 member heterocyclils), and aryl, heteroaryl, or heterocyclil can be any of the following: 7 It is replaced once, twice, or three times. Alternatively, two R's 5 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls, all of which can optionally be R 7 It can be substituted once, twice, or three times. R 6 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, Alternatively, two R's 6 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 7These are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, SO2NH2, SO2NH(C1-C6 alkyl), SO2N(C1-C6 alkyl)2, (CH2) 1~2 -OH, C(O)(CH2) 1~2 A substituent selected from the group consisting of -OH, C(O)(C1~C6alkyl), and C(O)O(C1~C6alkyl), Alternatively, two R's 7 These, together with the atoms to which they are bonded, can form 5-10 membered heteroaryls, 6-10 membered aryls, 3-10 membered heterocycloalkyls, or 3-10 membered cycloalkyls. R 8 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, 3-6 member cycloalkyl, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, R 9 The group consists of 6-10 membered aryls, 5-10 membered heteroaryls, 3-10 membered heterocycloalkyls, and 3-10 membered cycloalkyls, all of which have 1, 2, or 3 R 8 It can be arbitrarily replaced with.
[0055] In one embodiment, R 2 These are 6-10 membered aryls or 5-10 membered heteroaryls, both of which have 1, 2, or 3 Rs. 6 It is optionally replaced by R. In another embodiment, 2 is 1, 2, or 3 R 6 It is a 6-10 member aryl that is optionally substituted with R. In yet another embodiment, R 2 is 1, 2, or 3 R 6It is a 5-10 member heteroaryl that is optionally substituted with R. In another embodiment, R 2 is 1, 2, or 3 R 6 It is a phenyl compound optionally substituted with R. In one embodiment, R 2 is 1, 2, or 3 R 6 It is pyridyl as arbitrarily substituted.
[0056] In another embodiment, A and A' are independently CH2 or CHR 8 That is the case.
[0057] In another embodiment, the compound of formula I is the compound of formula II: [ka] or a pharmaceutically acceptable salt thereof.
[0058] In yet another embodiment, the compound of formula II is the compound of formula IIa: [ka] or a pharmaceutically acceptable salt thereof.
[0059] In yet another embodiment, the compound of formula I is the compound of formula III: [ka] or a pharmaceutically acceptable salt thereof.
[0060] In another embodiment, the compound of formula III is the compound of formula IIIa: [ka] or a pharmaceutically acceptable salt thereof.
[0061] In another embodiment, the compound of formula I is the compound of formula IV: [ka] or a pharmaceutically acceptable salt thereof.
[0062] In another embodiment, the compound of formula IV is the compound of formula IVa: [ka] or a pharmaceutically acceptable salt thereof.
[0063] In yet another embodiment, the compound of formula IV is the compound of formula IVb: [ka] or a pharmaceutically acceptable salt thereof.
[0064] In one embodiment of formulas IIa, IIIa, IVa, and IVb, R 1 The group consists of benzimidazole, imidazopyridine, indole, triazole, pyrazole, imidazole, pyridinylamide, and thiazolylamide, all of which have 1, 2, or 3 R 8 It is arbitrarily replaced with, R 6 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, R 7 These are C1-C3 alkyl groups, Each R 8 Each occurrence is independently selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, halogen, OH, and NH2.
[0065] In one embodiment, the compound of formula I is the compound of formula V: [ka] or a pharmaceutically acceptable salt thereof.
[0066] In another embodiment, the compound of formula I is the compound of formula VI: [ka] or a pharmaceutically acceptable salt thereof.
[0067] In yet another embodiment, the compound of formula I is the compound of formula VII: [ka] or a pharmaceutically acceptable salt thereof.
[0068] In another embodiment, the compound of formula I is the compound of formula VIII: [ka] or a pharmaceutically acceptable salt thereof.
[0069] In another embodiment, the compound of formula I is the compound of formula IX: [ka] or a pharmaceutically acceptable salt thereof.
[0070] In another embodiment, the compound of formula X is the compound of formula Xa: [ka] or a pharmaceutically acceptable salt thereof.
[0071] In yet another embodiment, the compound of formula X is the compound of formula Xb: [ka] or a pharmaceutically acceptable salt thereof.
[0072] In one embodiment, the compound of formula XX is the compound of formula XXa: [ka] or a pharmaceutically acceptable salt thereof.
[0073] In another embodiment, the compound of formula XXa is the compound of formula XXb: [ka] or a pharmaceutically acceptable salt thereof.
[0074] In yet another embodiment, the compound of formula XXa is the compound of formula XXc: [ka] or a pharmaceutically acceptable salt thereof.
[0075] In one embodiment or in formulas XXb and XXc, R 1 The group consists of benzimidazole, imidazopyridine, indole, triazole, pyrazole, imidazole, pyridinylamide, and thiazolylamide, all of which have 1, 2, or 3 R 8 It is arbitrarily replaced with, R 6 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O) 0~2 Selected from the group consisting of NH2 or CN, R 7 These are C1-C3 alkyl groups, R 8 Each occurrence is independently selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, halogen, OH, and NH2.
[0076] In one embodiment, R 3 Each occurrence is independent of halogen, OR 4 , NR 4 R 4 C(O)NHR 4 , C1-C6 alkyl, C2-C6 alkynyl, and C6-C 10 Selected from the group consisting of aryls, alkyl and alkynyl are R 4 It is optionally replaced 1, 2, or 3 times, and the aryl is R 5 It is replaced 1, 2, or 3 times as desired.
[0077] In another embodiment, R 3 is OR 4 In yet another embodiment, R 3 , NR 4 R 4 In another embodiment, R 3 R 4 It is a C2-C6 alkynyl that is optionally substituted 1, 2, or 3 times. In one embodiment, R 3 R 5 C6~C which are arbitrarily substituted 1, 2, or 3 times. 10 It is an arrow. In another embodiment, R 3 C(O)NHR 4 That is the case.
[0078] In yet another embodiment, R 3 In each occurrence, halogen, methyl, [ka] It is selected from the group consisting of the following.
[0079] In another embodiment, R 6 These are independently C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamine, halogen, OH, NO2, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, (CH2) 1~4 OH, S(O) 0~2 H, S(O)0~2 Selected from the group consisting of NH2 or CN. In another embodiment, R 6 In each occurrence, independently, it is hydroxyl or halo. In one embodiment, R 6 is chloro. In another embodiment, R 6 In yet another embodiment, R 6 It is hydroxyl.
[0080] In one embodiment, R 1 The group consists of benzimidazole, imidazopyridine, indole, triazole, pyrazole, imidazole, pyridinylamide, and thiazolylamide, all of which have 1, 2, or 3 R 8 It can be arbitrarily replaced with.
[0081] In another embodiment, R 1 teeth, [ka] Selected from the group consisting of, All of these are 1, 2, or 3 R's. 8 It can be arbitrarily replaced with.
[0082] In yet another embodiment, R 1 teeth, [ka] Selected from the group consisting of, All of these are 1, 2, or 3 R's. 8 It can be arbitrarily replaced with.
[0083] In another embodiment, R 1 teeth, [ka] That is the case.
[0084] In yet another embodiment, R 1 teeth, [ka] is.
[0085] In still another embodiment, R 1 is
Chemical Formula
[0086] In one embodiment, R 7 is C1-C3 alkyl. In another embodiment, R 7 is methyl.
[0087] In yet another embodiment, R 8 is independently at each occurrence selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, halogen, OH, and NH2.
[0088] In one embodiment, the compound of Formula I is selected from the group consisting of the compounds in Table 1.
Table 1-1
Table 1-2
Table 1-3
Table 1-4
[0089] In another embodiment, the compound of Formula X is selected from the group consisting of the compounds in Table 2.
Table 2-1
Table 2-2
[0090] In another embodiment, the compound of Formula XX is selected from the group consisting of the compounds in Table 3. [Table 3]
[0091] The compounds disclosed herein may exist as tautomers and optical isomers (for example, enantiomers, diastereomers, mixtures of diastereomers, racemic mixtures, and the like).
[0092] It is generally well known in the art that any compound that will be converted in vivo to provide a compound disclosed herein is a prodrug within the scope of the present disclosure.
[0093] In one aspect, provided herein is a pharmaceutical composition comprising any one of the compounds disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
[0094] In one embodiment, the composition further comprises a second active agent. In another embodiment, the second active agent is selected from the group consisting of a MEK inhibitor, a PI3K inhibitor, and an mTor inhibitor. In yet another embodiment, the second active agent prevents EGFR dimer formation in a subject. In still another embodiment, the second active agent is selected from the group consisting of cetuximab, trastuzumab, and panitumumab. In one embodiment, the second active agent is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0095] In another embodiment, this specification provides a pharmaceutical composition comprising a compound of the Disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical composition further comprises a second activator for preventing EGFR dimerization and a pharmaceutically acceptable carrier. In some embodiments, the second activator for preventing EGFR dimerization is an antibody. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab.
[0096] Compounds that bind to an allosteric site in EGFR, such as the compounds of the Disclosure (e.g., compounds of the formulas disclosed herein), optionally combined with a second activator, wherein the second activator prevents EGFR dimerization, can modulate EGFR activity. In some embodiments, the compounds of the Disclosure can inhibit or reduce EGFR activity without a second activator (e.g., an antibody such as cetuximab, trastuzumab, or panitumumab). In other embodiments, the compounds of the Disclosure are combined with a second activator. In one embodiment, the second activator can prevent EGFR dimerization and / or inhibit or reduce EGFR activity. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0097] Treatment method In one embodiment, a method is provided herein for treating cancer in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound disclosed herein. In one embodiment, the cancer is selected from the group consisting of lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, and prostate cancer. In another embodiment, the cancer is non-small cell lung cancer (NSCLC).
[0098] In another embodiment, a method is provided herein for inhibiting a kinase in an individual requiring such inhibition, comprising administering to the individual a therapeutically effective amount of a compound provided herein. In one embodiment, the kinase is EGFR.
[0099] In another embodiment, the Specified Publicly Provided is a method for treating or preventing a kinase-mediated disorder in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of the Publicly Provided. In one embodiment, the kinase-mediated disorder is resistant to EGFR-targeted therapy. In another embodiment, the EGFR-treated therapy is selected from the group consisting of gefitinib, erlotinib, or osimertinib.
[0100] In some embodiments, the compounds of the present disclosure can modulate (e.g., inhibit or reduce) the activity of EGFR containing one or more mutations. In some embodiments, the mutant EGFR contains one or more mutations selected from T790M, L718Q, L844V, V948R, L858R, I941R, C797S, and Del. In other embodiments, the mutant EGFR contains a combination of mutations selected from Del / L718Q, Del / L844V, Del / T790M, Del / T790M / L718Q, Del / T790M / L844V, L858R / L718Q, L858R / L844V, L858R / T790M, L858R / T790M / I941R, Del / T790M, Del / T790M / C797S, L858R / T790M / C797S, and L858R / T790M / L718Q. In other embodiments, the mutant EGFR contains a combination of mutations, selected from Del / L844V, L858R / L844V, L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M, Del / T790M / C797S, and L858R / T790M.
[0101] In some embodiments, the second activator prevents EGFR dimerization, and the compounds of the present disclosure in combination with the second activator can modulate (e.g., inhibit or reduce) the activity of EGFR containing one or more mutants. In some embodiments, the mutant EGFR contains one or more mutants selected from T790M, L718Q, L844V, V948R, L858R, I941R, C797S, and Del. In other embodiments, the mutant EGFR contains a combination of mutations selected from Del / L718Q, Del / L844V, Del / T790M, Del / T790M / L718Q, Del / T790M / L844V, L858R / L718Q, L858R / L844V, L858R / T790M, L858R / T790M / I941R, Del / T790M, Del / T790M / C797S, L858R / T790M / C797S, and L858R / T790M / L718Q. In other embodiments, the mutant EGFR contains a combination of mutations, selected from Del / L844V, L858R / L844V, L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M. In some embodiments, the second activator for preventing EGFR dimerization is an antibody. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib.
[0102] In some embodiments, the compounds of the present disclosure can modulate (e.g., inhibit or reduce) the activity of EGFR containing one or more mutations, but do not affect the activity of wild-type EGFR.
[0103] In other embodiments, the second activator prevents EGFR dimerization, and the compounds of the Disclosure combined with the second activator can modulate (e.g., inhibit or reduce) the activity of EGFR containing one or more mutations, but without affecting the activity of wild-type EGFR. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0104] Modification of EGFR, including one or more mutations such as those described herein rather than wild-type EGFR, provides approaches to the treatment, prevention, or improvement of diseases including, but not limited to, cancer and metastasis, inflammation, arthritis, systemic lupus erythematosus, skin-related disorders, lung disorders, cardiovascular diseases, ischemia, neurodegenerative disorders, liver diseases, gastrointestinal disorders, viral and bacterial infections, central nervous system disorders, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and peripheral neuropathy.
[0105] In some embodiments, the compounds of this disclosure exhibit greater inhibition of EGFR containing one or more of the mutations described herein compared to wild-type EGFR. In certain embodiments, the compounds of this disclosure exhibit inhibition at least 2, 3, 5, 10, 25, 50, or 100 times greater than wild-type EGFR. In various embodiments, the compounds of this disclosure exhibit inhibition up to 1000 times greater than wild-type EGFR. In various embodiments, the compounds of this disclosure exhibit inhibition up to 10000 times greater than wild-type EGFR of EGFR containing one or more of the mutations described herein.
[0106] In other embodiments, the compounds of the Disclosure, in combination with the second activator which prevents EGFR dimerization, exhibit greater inhibition of EGFR containing one or more mutations described herein compared to wild-type EGFR. In specific embodiments, the compounds of the Disclosure, in combination with the second activator which prevents EGFR dimerization, exhibit at least 2, 3, 5, 10, 25, 50, or 100 times greater inhibition of EGFR containing one or more mutations described herein compared to wild-type EGFR. In various embodiments, the compounds of the Disclosure, in combination with the second activator which prevents EGFR dimerization, exhibit up to 1000 times greater inhibition of EGFR containing one or more mutations described herein compared to wild-type EGFR. In various embodiments, the compounds of this disclosure, in combination with a second activator that prevents EGFR dimerization, exhibit up to 10,000-fold greater inhibition of EGFR having the mutation combinations described herein (e.g., L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M) compared to wild-type EGFR. In some embodiments, the second activator that prevents EGFR dimerization is an antibody. In further embodiments, the second activator that prevents EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator that prevents EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0107] In some embodiments, the compounds of this disclosure exhibit inhibition approximately 2 to 10 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein. In various embodiments, the compounds of this disclosure exhibit inhibition approximately 10 to 100 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein. In various embodiments, the compounds of this disclosure exhibit inhibition approximately 100 to 1000 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein. In various embodiments, the compounds of this disclosure exhibit inhibition approximately 1000 to 10000 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein.
[0108] In other embodiments, the compounds of the disclosure combined with the second activator, which prevents EGFR dimerization, exhibit inhibition approximately 2 to 10 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein. In other embodiments, the compounds of the disclosure combined with the second activator, which prevents EGFR dimerization, exhibit inhibition approximately 10 to 100 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein. In other embodiments, the compounds of the disclosure combined with the second activator, which prevents EGFR dimerization, exhibit inhibition approximately 100 to 1000 times greater than that of wild-type EGFR compared to EGFR containing one or more mutations described herein. In other embodiments, the second activator prevents EGFR dimerization, and the compounds of the Disclosure combined with the second activator exhibit approximately 1,000 to 10,000 times greater inhibition of EGFR containing one or more mutations described herein compared to wild-type EGFR. In other embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0109] In certain embodiments, the compounds of the Disclosure exhibit at least twice the inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the Disclosure exhibit at least three times the inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the Disclosure exhibit at least 5-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the Disclosure exhibit at least 10-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the Disclosure exhibit at least 25-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the Disclosure exhibit at least 50-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR.In certain embodiments, the compounds of the present disclosure exhibit at least 100-fold greater inhibition of EGFR having a combination of mutations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, as compared to wild-type EGFR.
[0110] In certain embodiments, the compounds of the present disclosure, in combination with a second activator that prevents EGFR dimerization, exhibit at least twice the inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the present disclosure, in combination with a second activator that prevents EGFR dimerization, exhibit at least three-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the present disclosure, in combination with the second activator which prevents EGFR dimerization, exhibit at least 5-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the present disclosure, in combination with a second activator that prevents EGFR dimerization, exhibit at least 10-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the present disclosure, in combination with a second activator that prevents EGFR dimerization, exhibit at least 25-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR.In certain embodiments, the compounds of the present disclosure, in combination with a second activator that prevents EGFR dimerization, exhibit at least 50-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In certain embodiments, the compounds of the Disclosure, in combination with the second activator that prevents EGFR dimerization, exhibit at least 100-fold greater inhibition of EGFR having mutation combinations selected from L858R / T790M, L858R / T790M / I941R, L858R / T790M / C797S, Del / T790M, Del / T790M / C797S, and L858R / T790M, compared to wild-type EGFR. In some embodiments, the second activator that prevents EGFR dimerization is an antibody. In further embodiments, the second activator that prevents EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator that prevents EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0111] In some embodiments, inhibition of EGFR activity is used in IC 50 It is measured by [method].
[0112] In some embodiments, inhibition of EGFR activity is EC 50 It is measured by [method].
[0113] In some embodiments, the inhibition of EGFR by the compounds of this disclosure can be measured via biochemical assays. By exemplary and non-limiting examples, homogeneous time-resolved fluorescence (HTRF) assays may be used to determine inhibition of EGFR activity using the conditions and experimental parameters disclosed herein. The HTRF assay may use, for example, a substrate concentration of about 1 μM (e.g., biotin-Lck-peptide substrate), a concentration of EGFR (mutant or WT) of about 0.2 nM to about 40 nM, and a concentration of inhibitor of about 0.000282 μM to about 50 μM. Compounds of this disclosure screened under these conditions may have ICs of, for example, about 1 nM to >1 μM, about 1 nM to about 400 nM, about 1 nM to about 150 nM, about 1 nM to about 75 nM, about 1 nM to about 40 nM, about 1 nM to about 25 nM, about 1 nM to about 15 nM, or about 1 nM to about 10 nM. 50 The values may be shown. In certain embodiments, compounds of the disclosure screened under the above conditions for EGFR inhibition having mutations or combinations of mutations selected from L858R / T790M, L858R, and T790M may have ICs of, for example, about 1 nM to > 1 μM, about 1 nM to about 400 nM, about 1 nM to about 150 nM, about 1 nM to about 75 nM, about 1 nM to about 40 nM, about 1 nM to about 25 nM, about 1 nM to about 15 nM, or about 1 nM to about 10 nM. 50 It can show a value.
[0114] In some embodiments, the compounds of the Disclosure bind to an allosteric site in EGFR. In some embodiments, the compounds of the Disclosure interact with at least one amino acid residue of the epidermal growth factor receptor (EGFR) selected from Lys745, Leu788, and Ala743. In other embodiments, the compounds of the Disclosure interact with at least one amino acid residue of the epidermal growth factor receptor (EGFR) selected from Cys755, Leu777, Phe856, and Asp855. In other embodiments, the compounds of the Disclosure interact with at least one amino acid residue of the epidermal growth factor receptor (EGFR) selected from Met766, Ile759, Glu762, and Ala763. In other embodiments, the compounds of the Disclosure interact with at least one amino acid residue of the epidermal growth factor receptor (EGFR) selected from Lys745, Leu788, and Ala743, at least one amino acid residue of the epidermal growth factor receptor (EGFR) selected from Cys755, Leu777, Phe856, and Asp855, and at least one amino acid residue of the epidermal growth factor receptor (EGFR) selected from Met766, Ile759, Glu762, and Ala763. In other embodiments, the compounds of the Disclosure do not interact with any of the amino acid residues of the epidermal growth factor receptor (EGFR) selected from Met793, Gly796, and Cys797.
[0115] In some embodiments, the present disclosure provides compounds comprising allosteric kinase inhibitors, which are more potent inhibitors of drug-resistant EGFR variants compared to wild-type EGFR. For example, the compounds may be at least about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or about 100-fold more potent in inhibiting the kinase activity of drug-resistant EGFR variants compared to wild-type EGFR. In some embodiments, drug-resistant EGFR variants are resistant to one or more known EGFR inhibitors, including, but not limited to, gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib.
[0116] In some embodiments, drug-resistant EGFR variants include sensitization mutations such as Del and L858R.
[0117] In some embodiments, the present disclosure provides compounds comprising an allosteric kinase inhibitor combined with a second activator, the second activator preventing EGFR dimerization, and the compound being a more potent inhibitor of drug-resistant EGFR variants compared to wild-type EGFR. For example, a compound combined with a second activator that prevents EGFR dimerization may be at least about 2, 3, 5, 10, 25, 50, or about 100 times more potent in inhibiting the kinase activity of drug-resistant EGFR variants compared to wild-type EGFR. In some embodiments, drug-resistant EGFR variants are resistant to one or more known EGFR inhibitors, including, but not limited to, gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib. In some embodiments, drug-resistant EGFR variants include sensitization mutations such as Del and L858R. In some embodiments, the second activator for preventing EGFR dimerization is an antibody. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In even further embodiments, the second activator for preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0118] In some embodiments, the present disclosure provides compounds comprising allosteric kinase inhibitors, wherein the compounds exhibit kinase activity (e.g., IC) of drug-resistant EGFR mutants having sensitizing mutations (e.g., Del and L858R) and drug-resistant mutations (e.g., T790M, L718Q, C797S, and L844V) compared to EGFR mutants having sensitizing mutations but not drug-resistance mutations. 50It inhibits with a potency difference of less than 10 times (as measured by...). In some embodiments, the potency difference is about 9 times, 8 times, 7 times, 6 times, 5 times, 4 times, 3 times, or less than 2 times.
[0119] In other embodiments, the disclosure provides a compound comprising an allosteric kinase inhibitor in combination with a second activator, wherein the second activator prevents EGFR dimerization, and the compound in combination with the second activator exhibits (e.g., IC) kinase activity of drug-resistant EGFR mutants having sensitizing mutations (e.g., Del and L858R) and drug-resistant mutations (e.g., T790M, L718Q, C797S, and L844V) compared to EGFR mutants having sensitizing mutations but not drug-resistant mutations. 50 Inhibits with a potency difference of less than 10 times (as measured by...). In some embodiments, the potency difference is about 9 times, 8 times, 7 times, 6 times, 5 times, 4 times, 3 times, or less than 2 times. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0120] In some embodiments, the Disclosure provides compounds comprising allosteric kinase inhibitors that are more potent than one or more known EGFR inhibitors, including but not limited to gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib, in inhibiting the activity of EGFR containing one or more mutations described herein, such as T790M, L718Q, L844V, L858R, C797S, and Del. For example, the compounds are more potent than gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib in inhibiting the activity of EGFR containing one or more mutations described herein (e.g., IC 50 (As measured by) it can be at least about 2 times, 3 times, 5 times, 10 times, 25 times, 50 times, or about 100 times stronger.
[0121] In other embodiments, the Disclosure provides a compound comprising an allosteric kinase inhibitor combined with a second activator, the second activator preventing EGFR dimerization, and the compound combined with the second activator is more potent than one or more known EGFR inhibitors, including, but not limited to, gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib, in inhibiting the activity of EGFR containing one or more mutations described herein, such as T790M, L718Q, L844V, L858R, C797S, and Del. For example, a compound in combination with a second activator that prevents EGFR dimerization inhibits the activity of EGFR containing one or more mutations described herein more effectively than gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib (e.g., IC 50It can be at least about 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or about 100-fold potency (as measured by...). In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0122] In some embodiments, the Disclosure provides compounds comprising allosteric kinase inhibitors, wherein the compounds are less potent in inhibiting wild-type EGFR activity than one or more known EGFR inhibitors, including but not limited to gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib. For example, the compounds are less potent in inhibiting wild-type EGFR activity than gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib (e.g., IC 50 (As measured by) the potency may be at least about 2, 3, 5, 10, 25, 50, or about 100 times lower.
[0123] In other embodiments, the Disclosure provides compounds comprising an allosteric kinase inhibitor combined with a second activator, wherein the second activator prevents EGFR dimerization, and the compound combined with the second activator is less potent in inhibiting wild-type EGFR activity than one or more known EGFR inhibitors, including, but not limited to, gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib. For example, the compound combined with the second activator, wherein the second activator prevents EGFR dimerization, is less potent in inhibiting wild-type EGFR activity than gefitinib, erlotinib, lapatinib, WZ4002, HKI-272, CL-387785, and osimertinib (e.g., IC 50 The potency may be at least about 2, 3, 5, 10, 25, 50, or about 100 times lower (as measured by...). In some embodiments, the second activator for preventing EGFR dimerization is an antibody. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0124] The effectiveness of the inhibitor is EC 50 It can be determined by the value. A lower EC will be determined under substantially similar conditions. 50 Compounds with a higher EC value 50 It is a more potent inhibitor compared to compounds with the same value. In some embodiments, substantially similar conditions include determining EGFR-dependent phosphorylation levels in vitro or in vivo (e.g., in 3T3 cells expressing wild-type EGFR, mutant EGFR, or fragments of either thereof).
[0125] The effectiveness of the inhibitor is also measured by IC. 50 It can be determined by the value. A lower IC will be determined under substantially the same conditions. 50 Compounds with a higher IC value 50 It is a more potent inhibitor compared to compounds with the same value. In some embodiments, substantially similar conditions include determining EGFR-dependent phosphorylation levels in vitro or in vivo (e.g., in 3T3 cells expressing wild-type EGFR, mutant EGFR, or fragments of either thereof).
[0126] EGFR sensitization mutations include, without limitation, L858R, G719S, G719C, G719A, L861Q, deletions in exon 19, and / or insertions in exon 20. Drug-resistant EGFR variants may have drug-resistant mutations including, without limitation, T790M, T854A, L718Q, C797S, or D761Y.
[0127] The selectivity between wild-type EGFR and EGFR containing one or more mutations as described herein can also be measured using cell proliferation assays if cell proliferation depends on kinase activity. For example, mouse Ba / F3 cells transfected with an appropriate version of wild-type EGFR (containing the WT EGFR kinase domain, such as VIII), or Ba / F3 cells transfected with L858R / T790M, Del / T790M / L718Q, L858R / T790M / L718Q, L858R / T790M / C797S, Del / T790M / C797S, L858R / T790M / I941R, or exon 19 deletion / T790M can be used. Growth assays were performed at various inhibitor concentrations (10 μM, 3 μM, 1.1 μM, 330 nM, 110 nM, 33 nM, 11 nM, 3 nM, 1 nM), and EC 50 This is calculated.
[0128] An alternative method for measuring the effect on EGFR activity is to assay EGFR phosphorylation. Wild-type or mutant (L858R / T790M, Del / T790M, Del / T790M / L718Q, L858R / T790M / C797S, Del / T790M / C797S, L858R / T790M / I941R, or L858R / T790M / L718Q) EGFR can be transfected into NIH-3 T3 cells (which normally do not express endogenous EGFR), and the ability of inhibitors to inhibit EGFR phosphorylation (using the concentrations mentioned above) can be assayed. Cells are exposed to increasing concentrations of the inhibitor for 6 hours and stimulated with EGF for 10 minutes. The effect on EGFR phosphorylation is assayed by Western blotting using a phospho-specific (Y1068) EGFR antibody.
[0129] In another aspect, the disclosure relates to compounds that bind to an allosteric site in EGFR, wherein the compounds exhibit inhibition greater than 2, 3, 5, 10, 25, 50, 100, or 1000 times greater than wild-type EGFR of EGFR containing one or more of the mutations described herein (e.g., L858R / T790M, Del / T790M, Del / T790M / L718Q).
[0130] In other embodiments, the Disclosure provides compounds that bind to allosteric sites in EGFR in combination with a second activator, the second activator preventing EGFR dimerization, and the compounds in combination with the second activator exhibit greater inhibition than 2-, 3-, 5-, 10-, 25-, 50-, 100-, or 1000-fold compared to wild-type EGFR containing one or more of the mutations described herein (e.g., L858R / T790M, Del / T790M, Del / T790M / L718Q). In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0131] In yet another embodiment, the Disclosure provides a method for inhibiting epidermal growth factor receptor (EGFR), the method comprising administering an effective amount of the compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a subject requiring such inhibition. In some embodiments, the method further comprises administering a second activator, the second activator preventing EGFR dimerization. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0132] In another embodiment, methods for treating or preventing a disease are provided herein, the methods comprising administering an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. In some embodiments, the disease is mediated by a kinase. In further embodiments, the kinase comprises a mutant cysteine residue. In further embodiments, the mutant cysteine residue is located at or near the position of Cys 797 in EGFR, including such positions in Jak3, Blk, Bmx, Btk, HER2 (ErbB2), HER4 (ErbB4), Itk, Tec, and Txk. In some embodiments, the methods further comprise administering a second activator, the second activator preventing kinase dimerization. In some embodiments, the second activator preventing kinase dimerization is an antibody. In further embodiments, the second activator prevents EGFR dimerization. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In yet another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0133] In some embodiments, the disease is mediated by EGFR (for example, EGFR plays a role in the onset or development of the disease). In some embodiments, the disease is mediated by Her-kinase. In further embodiments, the Her-kinase is HER1, HER2, or HER4.
[0134] In certain embodiments, the disease is resistant to known EGFR inhibitors, including but not limited to gefitinib, erlotinib, or osimertinib. In certain embodiments, diagnostic testing is performed to determine whether the disease is associated with an activating mutation in EGFR. In certain embodiments, diagnostic testing is performed to determine whether the disease is associated with EGFR having an activating mutation and / or a drug-resistant mutation. Activating mutations include, without limitation, L858R, G719S, G719C, G719A, L718Q, L861Q, deletions in exon 19, and / or insertions in exon 20. Drug-resistant EGFR variants may have drug-resistant mutations including, without limitation, T790M, T854A, L718Q, C797S, or D761Y. Diagnostic testing may include sequencing, pyrosequencing, PCR, RT-PCR, or similar analytical techniques known to those skilled in the art that can detect nucleotide sequences.
[0135] In certain embodiments, the disease is cancer or a proliferative disorder.
[0136] In further embodiments, the disease is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, or solid tumor. In further embodiments, the disease is lung cancer, breast cancer, glioma, squamous cell carcinoma, or prostate cancer. In even further embodiments, the disease is non-small cell lung cancer.
[0137] In certain embodiments, the disease is resistant to known EGFR inhibitors, including but not limited to gefitinib, erlotinib, or osimertinib. In certain embodiments, diagnostic testing is performed to determine whether the disease is associated with an activating mutation in EGFR. In certain embodiments, diagnostic testing is performed to determine whether the disease is associated with EGFR having an activating mutation and / or a drug-resistant mutation. Activating mutations include, without limitation, L858R, G719S, G719C, G719A, L718Q, L861Q, deletions in exon 19, and / or insertions in exon 20. Drug-resistant EGFR variants may have drug-resistant mutations including, without limitation, T790M, T854A, L718Q, C797S, or D761Y. Diagnostic testing may include sequencing, pyrosequencing, PCR, RT-PCR, or similar analytical techniques known to those skilled in the art that can detect nucleotide sequences.
[0138] In yet another embodiment, this specification provides a method for treating a kinase-mediated disorder, comprising administering an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. In some embodiments, the compound is an inhibitor of HER1, HER2, or HER4. In other embodiments, the subject is administered an additional therapeutic agent. In other embodiments, the compound and the additional therapeutic agent are administered simultaneously or sequentially.
[0139] In another embodiment, the present disclosure provides a method for treating a kinase-mediated disorder, comprising administering to a subject in need of such treatment an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a second activator, wherein the second activator prevents EGFR dimerization. In some embodiments, the compound is an inhibitor of HER1, HER2, or HER4. In other embodiments, the subject is administered an additional therapeutic agent. In other embodiments, the compound, the second activator preventing EGFR dimerization, and the additional therapeutic agent are administered simultaneously or sequentially. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib.
[0140] In other embodiments, the disease is cancer. In further embodiments, cancer is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, or solid tumor. In further embodiments, the disease is lung cancer, breast cancer, glioma, squamous cell carcinoma, or prostate cancer. In even further embodiments, the disease is non-small cell lung cancer.
[0141] In another embodiment, this specification provides a method for treating cancer, wherein cancer cells contain activated EGFR, and the method comprises administering an effective amount of one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof to a subject in need of treatment.
[0142] In another embodiment, this specification provides a method for treating cancer, wherein cancer cells contain activated EGFR and the method comprises administering to a subject in need of treatment an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and a second activator, wherein the second activator prevents EGFR dimerization. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0143] In certain embodiments, EGFR activation is selected from EGFR mutation, EGFR amplification, EGFR expression, and ligand-mediated activation of EGFR.
[0144] In further embodiments, the EGFR mutation is selected from G719S, G719C, G719A, L858R, L861Q, exon 19 deletion mutations, and exon 20 insertion mutations.
[0145] In yet another embodiment, the Specified Method for Treating Cancer in a Subject is provided, wherein the subject is identified as requiring EGFR inhibition for the treatment of the cancer, and the method comprises administering to the subject an effective amount of one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof.
[0146] In certain embodiments, subjects identified as requiring EGFR inhibition are resistant to known EGFR inhibitors, including, but not limited to, gefitinib, erlotinib, or osimertinib. In certain embodiments, diagnostic testing is performed to determine whether the subject has an activating mutation in EGFR. In certain embodiments, diagnostic testing is performed to determine whether the subject has EGFR with an activating mutation and / or a drug-resistant mutation. Activating mutations include, without limitation, L858R, G719S, G719C, G719A, L718Q, L861Q, deletions in exon 19, and / or insertions in exon 20. Drug-resistant EGFR variants may have drug-resistant mutations including, without limitation, T790M, T854A, L718Q, C797S, or D761Y. Diagnostic testing may include sequencing, pyrosequencing, PCR, RT-PCR, or similar analytical techniques known to those skilled in the art that can detect nucleotide sequences.
[0147] In one embodiment, the Specified provides a method for preventing resistance in a subject to a known EGFR inhibitor (including, but not limited to, gefitinib, erlotinib, or osimertinib), comprising administering an effective amount of one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof to the subject in need.
[0148] In another embodiment, this specification provides a method for preventing resistance to known EGFR inhibitors (including, but not limited to, gefitinib, erlotinib, or osimertinib) in a disease, comprising administering to a subject in need of such prevention an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and a second activator, wherein the second activator prevents EGFR dimerization. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab.
[0149] In one embodiment of the method disclosed herein, the subject is a human being.
[0150] In another aspect, the disclosure provides compounds disclosed herein, or pharmaceutically acceptable salts thereof, for use in the manufacture of pharmaceuticals for treating or preventing diseases in which EGFR plays a role.
[0151] In one embodiment, the Specified Public Service provides a method for treating or preventing a condition selected from the group consisting of autoimmune diseases, inflammatory diseases, proliferative and hyperproliferative diseases, immunologically mediated diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cardiovascular diseases, hormone-related diseases, allergies, asthma, and Alzheimer's disease. In other embodiments, the condition is selected from proliferative disorders and neurodegenerative disorders.
[0152] One aspect of this disclosure provides compounds useful for treating diseases, disorders, and conditions characterized by excessive or abnormal cell proliferation. Such diseases include, but are not limited to, proliferative or hyperproliferative disorders and neurodegenerative disorders. Examples of proliferative and hyperproliferative disorders include, but are not limited to, cancer. The term "cancer" includes, but is not limited to, cancers of the breast, ovaries, cervix, prostate, testes, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanocyte, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, colorectal, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, anaplastic carcinoma, papillary carcinoma, seminomas, melanoma, sarcoma, bladder cancer, liver and biliary tract cancer, kidney cancer, bone marrow disorders, lymphatic disorders, Hodgkin's disease, hair cell cancer, buccal and pharynx (oral cavity), lips, tongue, mouth, pharynx, small intestine, colon, rectum, large intestine, rectum, brain and central nervous system, chronic myeloid leukemia (CML), and leukemia. The term "cancer" is not limited to, but includes the following cancers: myeloma, lymphoma, or cancer selected from stomach, kidney, head and neck, oropharyngeal, non-small cell lung (NSCLC), endometrial, liver cancer, non-Hodgkin lymphoma, and lung cancer.
[0153] The term "cancer" refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas. For example, cancer includes, but is not limited to, mesothelioma, leukemia, and lymphoma, such as cutaneous T-cell lymphoma (CTCL), non-cutaneous peripheral T-cell lymphoma, lymphoma associated with human T-cell lymphotrophic virus (HTLV), such as adult T-cell leukemia / lymphoma (ATLL), B-cell lymphoma, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, lymphoma, and multiple myeloma, non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, Burkitt lymphoma, adult T-cell leukemia / lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or hepatocellular carcinoma. Further examples include myelodysplastic syndromes, pediatric solid tumors such as brain tumors, neuroblastomas, retinoblastomas, Wilms' tumors, bone tumors, and soft tissue sarcomas, common solid tumors in adults such as head and neck cancers (e.g., oral cavity, larynx, nasopharynx, and esophagus), genitourinary cancers (e.g., prostate, bladder, kidney, uterus, ovaries, and testes), lung cancers (e.g., small cell and non-small cell), breast cancer, pancreatic cancer, melanoma, and other skin cancers, gastric cancer, brain tumors, tumors associated with Gorin syndrome (e.g., medulloblastoma, meningioma, etc.), and liver cancer. Additional exemplary forms of cancer that can be treated with the compound include, but are not limited to, cancers of the skeletal or smooth muscle, gastric cancer, small intestine cancer, rectal cancer, salivary gland cancer, endometrial cancer, adrenal cancer, anal cancer, parathyroid cancer, and pituitary cancer.
[0154] Additional cancers for which the compounds described herein may be useful in prevention, treatment, and research include, for example, colorectal cancer, familial adenomatous polyposis, and hereditary nonpolyposis colorectal cancer, or melanoma. Furthermore, cancers include, but are not limited to, labial cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, thyroid cancer (medullary and papillary thyroid cancer), renal cancer, renal parenchymal cancer, cervical cancer, uterine cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary cancer, melanoma, brain tumors, such as glioblastoma, astrocytoma, meningioma, medulloblastoma, and peripheral neuroectodermal tumors, gallbladder cancer, bronchial cancer, multiple myeloma, basal tumor, teratoma, retinoblastoma, choroidal melanoma, seminomas, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myasthenia, liposarcoma, fibrosarcoma, Ewing's sarcoma, and plasmacytoma. In one aspect of this disclosure, the disclosure provides the use of one or more compounds of this disclosure in the manufacture of a pharmaceutical product for the treatment of cancer, including, without limitation, various types of cancer disclosed herein.
[0155] In some embodiments, the compounds of the Disclosure are useful for treating cancers such as colorectal cancer, thyroid cancer, breast cancer, and lung cancer, as well as myeloproliferative disorders such as polycythemia vera, thrombocythemia, myelometaplasia with myelofibrosis, chronic myeloid leukemia, chronic myelomonocytic leukemia, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease. In some embodiments, the compounds of the Disclosure are useful for treating hematopoietic disorders, particularly acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute promyelocytic leukemia, and acute lymphoblastic leukemia (ALL).
[0156] The term “cancer cell” as provided herein includes cells that are suffering from any one of the conditions identified above.
[0157] This disclosure further provides methods for treating or preventing cell proliferation disorders such as hyperplasia, dysplasia, and precancerous lesions. Dysplasia is the earliest form of precancerous lesions recognizable by biopsy by a pathologist. The compounds may be administered for the purpose of preventing the hyperplasia, dysplasia, or precancerous lesion from continuing to enlarge or becoming cancerous. Examples of precancerous lesions may occur in the skin, esophageal tissue, breast, and intraepithelial tissue of the cervix.
[0158] Examples of neurodegenerative diseases include, without limitation, adrenoleukodystrophy (ALD), Alexander disease, Alperz disease, Alzheimer's disease, amyotrophic lateral sclerosis (Lou Gehrig's disease), ataxia with telangiectasia, Batten disease (also known as Spillmayer-Voigt-Sjögren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, familial fatal insomnia, frontotemporal lobar degeneration, Huntington's disease, HIV-related dementia, Kennedy disease, Krabbe disease, Lewy body dementia, neuroborreliosis, and Machado disease. - These include Joseph's disease (spinocerebellar ataxia type 3), multiple system atrophy, multiple sclerosis, narcolepsy, Niemann-Pick disease, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion disease, progressive supranuclear palsy, Refsum disease, Sandhoff disease, Schilder's disease, subacute combined degeneration of the spinal cord, secondary to pernicious anemia, Spillmayer-Voigt-Sjögren-Batten disease (also known as Batten disease), spinocerebellar degeneration (multiple types with different characteristics), spinal muscular atrophy, Steele-Richardson-Olzewski disease, tabes dorsalis, and toxic encephalopathy.
[0159] Another aspect of this disclosure provides a method for treating or reducing the severity of a disease selected from proliferative or hyperproliferative diseases or neurodegenerative diseases, comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition containing the compound, to a subject in need thereof. In other embodiments, the method further comprises administering a second activator, the second activator preventing EGFR dimerization. In some embodiments, the second activator preventing EGFR dimerization is an antibody. In further embodiments, the second activator preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator preventing EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0160] The activity of the compounds and compositions of this disclosure as EGFR kinase inhibitors can be assayed in vitro, in vivo, or in cell lines. In vitro assays include assays that determine inhibition of either the kinase activity or ATPase activity of an activated kinase. Alternative in vitro assays may quantify the ability of an inhibitor to bind to a protein kinase, by either radiolabeling the inhibitor before binding, isolating the inhibitor / kinase complex, determining the amount of radiolabeled material bound, or by performing competitive experiments in which a novel inhibitor is incubated with a kinase bound to a known radioligand. Detailed conditions for assaying the compounds used in this disclosure as inhibitors of various kinases are described in the following examples.
[0161] As stated above, the present disclosure further provides methods for preventing or treating any of the above-mentioned diseases or disorders in a subject requiring such treatment, the methods comprising administering to the subject a therapeutically effective amount of the compound of the present disclosure or a pharmaceutically acceptable salt thereof, and optionally a second activator, the second activator being an inhibitor of EGFR dimerization. For any of the above uses, the required dose will vary depending on the mode of administration, the specific condition being treated, and the desired effect.
[0162] In other embodiments, the compound and a second activator that prevents EGFR dimerization are administered simultaneously or sequentially.
[0163] Dosage / Formulation Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsifies, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may contain, for example, water or other solvents, solubilizers, and emulsifiers, such as inert diluents commonly used in the art, including ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and oma oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as mixtures thereof. Beyond inert diluents, the oral composition may also contain adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and fragrances.
[0164] Injectable preparations (e.g., sterile injectable aqueous or oily suspensions) can be formulated according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions, suspensions, or emulsions in non-toxic, parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP, and isotonic sodium chloride solutions. Furthermore, sterile fixative oils are conventionally used as solvents or suspension media. For this purpose, any brand of fixative oil, including synthetic mono- or diglycerides, can be used. In addition, fatty acids such as oleic acid may be used in the preparation of injectable preparations.
[0165] To prolong the effects of a drug, it is often desirable to delay its absorption via subcutaneous or intramuscular injection. This can be achieved by using liquid suspensions of crystalline or amorphous materials with low water solubility. In this case, the absorption rate of the drug depends on its dissolution rate, which in turn may depend on the crystal size and morphology. Alternatively, delayed absorption of parenterally administered drug forms can be achieved by dissolving or suspending the drug in an oily vehicle.
[0166] Compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the compounds of the present disclosure with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or suppository wax, which is solid at ambient temperature but liquid at body temperature, and therefore melts in the rectal or vaginal cavity, releasing the active compound.
[0167] Similar types of solid compositions can also be used as fillers in soft and hard gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol.
[0168] The active compound may also be in a microencapsulated form having one or more of the excipients described above. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings, controlled-release coatings, and other coatings, which are well known in the pharmaceutical field. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. According to conventional methods, such dosage forms may also contain additional substances other than the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage form may also contain a buffer.
[0169] Dosage forms for topical or transdermal administration of the compounds of this disclosure include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredients are mixed under sterile conditions with a pharmaceutically acceptable carrier and, if necessary, any required preservatives or buffers. Ophthalmic formulations, ear drops, eye ointments, powders, and solutions are also intended to be within the scope of this disclosure.
[0170] In addition to the active compounds of this disclosure, the ointments, pastes, creams, and gels may contain excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof.
[0171] The powders and sprays may contain, in addition to the compounds of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures thereof. The sprays may also contain conventional propellants such as chlorofluorohydrocarbons.
[0172] Transdermal patches offer the additional advantage of providing controlled delivery of compounds to the body. Such drug delivery forms can be prepared by dissolving or distributing the compound in a suitable culture medium. Absorption enhancers can also be used to increase the flow of the compound across the skin. The rate can be controlled either by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or gel.
[0173] According to the therapeutic methods of the Disclosure, a disorder is treated or prevented in a subject, such as a human or other animal, by administering to the subject a therapeutically effective dose of the compound of the Disclosure in the amount and time required to achieve the desired outcome. The term “therapeutic dose” of the compound of the Disclosure, as used herein, means an amount of the compound sufficient to reduce the symptoms of the disorder in the subject. As is well understood in the medical field, the therapeutically effective dose of the compound of the Disclosure would be in a reasonable benefit-risk ratio applicable to any medical treatment.
[0174] Generally, the compounds of this disclosure will be administered in therapeutically effective doses, either alone or in combination with one or more therapeutic agents, via any of the usual and acceptable forms known in the art. The therapeutically effective dose may vary widely depending on the severity of the disease, the age and relative health status of the subject, the potency of the compound used, and other factors. Generally, favorable results have been shown to be obtained systemically with a daily dose of about 0.03 to 2.5 mg / kg per body weight. In larger mammals, e.g., humans, the indicated daily dose ranges from about 0.5 mg to about 100 mg and is conveniently administered, for example, in divided doses up to four times a day, or in delayed forms. A preferred unit dosing form for oral administration contains about 1 to 50 mg of the active ingredient.
[0175] In certain embodiments, the therapeutic dose or size of the compounds of this disclosure may range from about 0.1 mg / kg to about 500 mg / kg, or from about 1 to about 50 mg / kg. Generally, the therapeutic regimens according to this disclosure involve administering a single or multiple dose of about 10 mg to about 1000 mg of the compounds of this disclosure per day to patients requiring such treatment. The therapeutic dose or size will also vary depending on the route of administration and the possibility of concomitant use with other drugs.
[0176] When the subject's condition improves, a maintenance dose of the compound, composition, or combination of the disclosure may be administered as needed. Thereafter, the dose, frequency, or both may be reduced as a function of the symptoms to a level that maintains the improved condition, and treatment should be discontinued when the symptoms have been reduced to the desired level. However, the subject may require long-term, intermittent treatment when symptoms of the disease recur.
[0177] However, it will be understood that the total daily dose of the compounds and compositions disclosed herein will be determined by the attending physician within the bounds of sound medical judgment. The specific inhibitory dose for a particular patient will depend on a variety of factors, including the disorder being treated and its severity, the activity of the specific compound used, the specific composition used, the patient's age, weight, general health, sex, and diet, the timing of administration, route of administration, and excretion rate of the specific compound used, the duration of treatment, any drugs used in combination with or concurrently with the specific compound used, and similar factors well known in the medical field.
[0178] The Disclosure also provides a pharmaceutically acceptable combination, e.g., a kit, comprising a) a first agent, which is a compound of the Disclosure disclosed herein, in free form or in a pharmaceutically acceptable salt form, and b) at least one adjuvant. The kit may include instructions for its administration.
[0179] In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents. For example, agents that prevent EGFR dimerization, chemotherapeutic agents, or other antiproliferative agents may be combined with the compounds of the Disclosure to treat proliferative disorders and cancers.
[0180] Some examples of materials that can function as pharmaceutically acceptable carriers are, but are not limited to, ion exchangers; alumina; aluminum stearate; lecithin; serum proteins, e.g., human serum albumin; buffers, e.g., phosphates, glycine, sorbic acid, or potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes, e.g., protamine sulfate; disodium hydrogen phosphate; potassium hydrogen phosphate; sodium chloride; zinc salts; colloidal silica; magnesium trisilicate; polyvinylpyrrolidone; polyacrylates; waxes; polyethylene polyoxypropylene block polymers; lanolin; sugars, e.g., lactose, glucose, and sucrose; starch, e.g. The composition may also include corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository wax; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol or polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline solution; Ringer's solution; ethyl alcohol; and phosphate buffer solutions. Furthermore, non-toxic compatible lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as colorants, release agents, coating agents, sweeteners, flavorings, and fragrances, preservatives, and antioxidants may also be present in the composition at the discretion of the formulation. Protein kinase inhibitors or their pharmaceutically acceptable salts can be formulated into pharmaceutically acceptable compositions for administration to animals or humans. These pharmaceutically acceptable compositions, comprising an effective amount of a protein inhibitor to treat or prevent a protein kinase-mediated condition and a pharmaceutically acceptable carrier, are other embodiments of the present disclosure.
[0181] kit In one embodiment, a kit is provided comprising a compound, or a pharmaceutically acceptable salt thereof, that can inhibit kinase activity selected from one or more compounds disclosed herein, and instructions for use in the treatment of cancer. In certain embodiments, the kit further comprises components for performing a test to determine whether a subject has an activating and / or drug-resistant mutation in EGFR.
[0182] In another embodiment, the present disclosure provides a kit comprising a compound, or a pharmaceutically acceptable salt thereof, that can inhibit EGFR activity selected from the compounds disclosed herein.
[0183] In another embodiment, the Disclosure provides a kit comprising a compound, or a pharmaceutically acceptable salt thereof, that can inhibit kinase activity selected from one or more compounds disclosed herein, a second activator for preventing EGFR dimerization, and instructions for use in the treatment of cancer. In certain embodiments, the kit further comprises components for performing a test to determine whether a subject has an activating and / or drug-resistant mutation in EGFR. In some embodiments, the second activator for preventing EGFR dimerization is an antibody. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator for preventing EGFR dimerization is cetuximab.
[0184] In another embodiment, the Disclosure provides a kit comprising a compound, or a pharmaceutically acceptable salt thereof, that can inhibit EGFR activity selected from the compounds disclosed herein, and a second activator that prevents EGFR dimerization. In some embodiments, the second activator that prevents EGFR dimerization is an antibody. In further embodiments, the second activator that prevents EGFR dimerization is cetuximab, trastuzumab, or panitumumab. In further embodiments, the second activator that prevents EGFR dimerization is cetuximab. In one embodiment, the second activator is an ATP-competitive EGFR inhibitor. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib, gefitinib, or erlotinib. In another embodiment, the ATP-competitive EGFR inhibitor is osimertinib.
[0185] This disclosure is further illustrated by the following examples and synthesis schemes, which should not be considered to limit the scope or spirit of this disclosure to the specific procedures described herein. It should be understood that the examples are provided to illustrate certain embodiments and that no limitation is intended to the scope of this disclosure. It should also be understood that various other embodiments, modifications, and equivalents can be taken, which themselves may be suggested to those skilled in the art without departing from the spirit of this disclosure and / or the appended claims. [Examples]
[0186] This application is further illustrated by the following examples, which should not be construed as a further limitation. Unless otherwise indicated, the practice of this disclosure will utilize the prior art of organic synthesis, cell biology, cell culture, and molecular biology, which is within the scope of the skill in the art. [Table 4]
[0187] Example 1: Preparation of 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]-triazine-3(4H)-yl)-2-phenyl-N-(thiazole-2-yl)acetamide hydrochloride (001) [ka] 2-(6-bromo-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-methylphenylacetate [ka] A mixture of 6-bromopyrrolo[2,1-f][1,2,4]triazine-4(3H)-one (321 mg, 1.5 mmol), 2-bromo-2-phenylacetate methyl (378 mg, 1.65 mmol), Cs2CO3 (975 mg, 3.0 mmol), and DMF (3 mL) was stirred at 50°C for 1.5 hours. Another aliquot of 2-bromo-2-phenylacetate methyl (147 mg, 0.65 mmol) was added, and the reaction mixture was heated for a further 1 hour. After cooling, the reaction mixture was poured into saturated brine (10 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic extract was washed with saturated brine, dried over Na2SO4, filtered, concentrated under reduced pressure, and purified by normal-phase flash chromatography (0-75% ethyl acetate / hexane) to obtain the title compound (445 mg, 82%).
[0188] 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-phenylacetic acid [ka] A mixture of dioxane (1.5 mL) under N2 in a sealed vial and 2-(6-bromo-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-phenyl-methyl acetate (100 mg, 0.028 mmol), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl)piperidine (92 mg, 0.3 mmol), Na2CO3 (89 mg, 0.84 mmol), and Pd(dppf)Cl2-DCM (46 mg, 0.056 mmol) in H2O (0.5 mL) was heated at 95°C for 16 hours. The mixture was cooled, filtered through a syringe filter, and purified by reverse-phase HPLC eluting with 0-80% ACN / H2O (0.038% TFA modifier) to obtain the title compound (125 mg, 78%). 1 H NMR(500MHz,DMSO-d6)δ 9.40(br s,1H)8.17(d,1H)7.82(s,1H)7.74(d,2H)7.51(m,r2H)7.46(m,3H)7.43(d,1H)7.26(d, 2H)6.46(s,1H)3.53(d,2H)3.08(m,2H)2.83(d,3H)2.81(m,1H)2.03(d,2H)1.84(m,2H).
[0189] 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-phenyl-N-(thiazole-2-yl)acetamide hydrochloride (001) [ka] A mixture of 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-phenylacetic acid (60 mg, 0.14 mmol), 2-aminothiazole (20 mg, 0.20 mmol), HATU (103 mg, 0.27 mmol), and DIEA (71 μL, 0.41 mmol) in DMF (2 mL) was stirred at 50°C for 1.5 hours. After cooling, the reaction mixture was purified by reverse-phase HPLC eluting with 0-80% ACN / H2O (0.038% TFA modifier). The crude product was further purified by silica chromatography (0-10% 7N methanol NH3 in DCM). The residue was dissolved in MeOH (5 mL), treated with 4N HCl / dioxane (0.5 mL), and concentrated under reduced pressure. The residue was ground with Et2O, filtered, and dried to obtain the title compound (57 mg, 79%). 1 H NMR(500MHz,DMSO-d6)δ 9.33(br s,1H)8.19(d,1H)7.75(d,2H)7.57(s,1H)7.51(m,4H)7.44(m,3H)7.33(d,1H)7.26(d,1 H)6.81(s,1H)3.53(d,2H)3.08(m,2H)2.84(d,3H)2.81(m,1H)2.03(m,2H)1.83(m,2H).
[0190] The following examples were prepared from methyl 2-bromo-2-phenylacetate and the corresponding bicyclic starting material using the same method as in Example 1. [Table 5]
[0191] Example 2: Preparation of 3-((1H-benzo[d]imidazole-2-yl)(phenyl)methyl)-6-(4-(1-methylpiperidine-4-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazine-4(3H)-one hydrochloride (002) [ka] N-(2-aminophenyl)-2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]-triazine-3(4H)-yl)-2-phenylacetamide [ka] A mixture of 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-phenylacetic acid (60 mg, 0.14 mmol), benzene-1,2-diamine (75 mg, 0.69 mmol), HATU (174 mg, 0.46 mmol), and DIEA (120 μL, 0.69 mmol) in DMF (3 mL) was stirred at 50 °C for 1 hour. After cooling, the mixture was purified by reverse-phase HPLC eluting with 0-80% ACN / H2O (0.038% TFA modifier) to obtain the title compound (80 mg, 65%). 1 H NMR(500MHz,DMSO-d6)δ 9.97(s,1H)9.32(br s,1H)8.17(d,1H)7.75(d,2H)7.63(s,1H)7.53(m,4H)7.48(m,1H)7.46(d,1H)7.26(d,2H)7.23(dd,1H)6.98(m,1 H)6.82(s,1H)6.78(dd,1H)6.61(m,1H)3.53(d,2H)3.08(m,2H)2.83(d,3H)2.81(m,1H)2.03(d,2H)1.83(m,2H).
[0192] 3-((1H-benzo[d]imidazole-2-yl)(phenyl)methyl)-6-(4-(1-methylpiperidine-4-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazine-4(3H)-one hydrochloride (002) [ka] A solution of N-(2-aminophenyl)-2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxopyrrolo[2,1-f][1,2,4]triazine-3(4H)-yl)-2-phenylacetamide (80 mg, 0.15 mmol) and AcOH (3 mL) was heated at 100 °C for 1 hour. Excess AcOH was removed under reduced pressure. The residue was dissolved in ELISA (5 mL) and washed with 1 N NaOH (5 mL), water (5 mL), and saturated brine (5 mL). The organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica chromatography (0-5% 7 N methanol NH3 / DCM), the product was dissolved in MeOH (5 mL), treated with 4 N HCl in dioxane (1 mL), and concentrated under pressure. The obtained solid was pulverized with Et2O, filtered, and dried to obtain the title compound (19 mg, 25%). 1 H NMR(500MHz,DMSO-d6)δ 10.09(br s,1H)8.21(d,1H)8.08(s,1H)7.75(d,2H)7.64(m,2H)7.51(s,1H)7.48(m,4H)7.44(m,2 H)7.30(m,2H)7.26(d,2H)3.50(d,2H)3.06(m,2H)2.80(m,1H)2.79(d,3H)1.96(m,4H).
[0193] The following examples were prepared from methyl 2-bromo-2-phenylacetate and the corresponding bicyclic starting material using the same method as in Example 2. [Table 6]
[0194] Example 3: Preparation of 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-phenyl-N-(thiazole-2-yl)acetamide (003) [ka] 2-(6-bromo-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-methylphenylacetate [ka] A mixture of 6-bromothieno[3,2-d]pyrimidine-4(3H)-one (250 mg, 1.08 mmol), 2-bromo-2-phenylacetate methyl (296 mg, 1.29 mmol), and Cs2CO3 (543 mg, 1.5 mmol) in DMF (3 mL) was stirred at 50°C for 2 hours. After cooling, the reaction mixture was poured into saturated brine (approximately 30 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic extract was dried over Na2SO4, filtered, concentrated under reduced pressure, purified by normal-phase flash chromatography, and eluted (0-50% ethyl acetate / hexane) to obtain the title compound (250 mg, 61%). 1 H NMR(500MHz,DMSO-d6)δ 8.47(s,1H)8.37(s,1H)7.52(m,2H)7.45(m,3H)6.64(s,1H)3.77(s,3H).
[0195] 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-phenylacetate methyl [ka] A mixture of 2-(6-bromo-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-phenylmethyl acetate (250 mg, 0.83 mmol), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-piperidine (275 mg, 0.91 mmol), Pd(dppf)Cl2-DCM (68 mg, 0.083 mmol), and Na2CO3 (264 mg, 2.89 mmol) in dioxane (3.0 mL) and water (1.0 mL) was heated in a sealed vial under N2 conditions and heated at 100°C for 1 hour. After cooling, the reaction mixture was filtered through a syringe filter and purified by reverse-phase HPLC eluting with 0-80% ACN / H2O (0.038% TFA modifier) to obtain the title compound (65 mg, 16%).
[0196] 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-phenylacetic acid [ka] A mixture of 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-phenylacetate methyl (65 mg, 0.14 mmol), LiOH-H2O (24 mg, 0.72 mmol), THF (1.0 mL), MeOH (1 mL), and water (1 mL) was stirred for 60 minutes. The solvent was removed under reduced pressure, and the residue was dissolved in water (5 mL). The pH of the solution was adjusted to pH 5 (pH paper) with 1.5 N HCl. The precipitate was pulverized with water (2 × 5 mL), filtered, and dried overnight at 60°C under high vacuum to obtain the title compound (64 mg, quantified), which was used in subsequent steps without further purification.
[0197] 2-(6-(4-(1-methylpiperidine-4-yl)phenyl)-4-oxothieno[3,2-d]pyrimidine-3(4H)-yl)-2-phenyl-N-(thiazole-2-yl)acetamide(003) [ka] This compound was prepared in the same manner as compound 001 from the acid described above, and purified by reverse-phase HPLC eluting with 0-80% ACN / H2O (0.038% TFA modifier) to obtain the title compound (43 mg, 94%).
[0198] Example 4: 5-[1H-benzimidazole-2-yl-(5-fluoro-2-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6,7-dihydrothieno[3,2-c]pyridine-4-one dihydrochloride (012) [ka] Step 1.2-(2-bromo-4-oxo-6,7-dihydrothieno[3,2-c]pyridine-5-yl)-2-(5-fluoro-2-methoxyphenyl)methyl acetate [ka] To a solution of 2-bromo-6,7-dihydrothieno[3,2-c]pyridine-4(5H)-one (0.300 g, 1.29 mmol) in THF (6 mL), sodium hydride (0.077 g, 1.93 mmol, 60% in mineral oil) was added at 0°C. After stirring at the same temperature for 0.5 hours, a solution of 2-bromo-2-(5-fluoro-2-methoxyphenyl)-methyl acetate (0.714 g, 2.58 mmol) in THF (4 mL) was added dropwise to the reaction mixture. After stirring at room temperature for 2 hours, the reaction mixture was quenched with water and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (0.552 g, quantified). MS m / z: 428.0 [M+1] + .
[0199] Step 2.2-(2-bromo-4-oxo-6,7-dihydrothieno[3,2-c]pyridine-5-yl)-2-(5-fluoro-2-methoxyphenyl)acetic acid [ka] To a solution of methyl 2-(2-bromo-4-oxo-6,7-dihydrothieno[3,2-c]pyridine-5-yl)-2-(5-fluoro-2-methoxyphenyl)acetate (0.552 g, 1.28 mmol) in THF / water (20 mL, 1 / 1), lithium hydroxide (0.092 g, 3.84 mmol) was added. After stirring at room temperature for 1 hour, the solvent was removed under reduced pressure, and the resulting residue was adjusted to pH 3 with HCl (1 M). The resulting solid was collected by filtration and washed with water to obtain the title compound (0.45 g, 85%). 1H NMR(DMSO-d6)δ:7.35(s,1H),7.16-7.25(m,1H),7.06-7.14(m,1H),6.97-7.05(m,1H) ,6.17(s,1H),3.76(s,3H),3.61-3.70(m,1H),3.25-3.27(m,1H),2.77-3.05(m,2H);MS m / z:414.1[M+1] + .
[0200] Step 3.5-[1H-benzimidazole-2-yl-(5-fluoro-2-methoxyphenyl)methyl]-2-bromo-6,7-dihydrothieno[3,2-c]pyridine-4-one [ka] A solution of 2-(2-bromo-4-oxo-6,7-dihydrothieno[3,2-c]pyridin-5-yl)-2-(5-fluoro-2-methoxyphenyl)acetic acid (0.450 g, 1.08 mmol), 1,2-diaminobenzene (0.174 g, 1.61 mmol), and HATU (0.612 g, 1.61 mmol) in DMF (8 mL) was mixed with DIPEA (0.562 mL, 3.23 mmol). After stirring at room temperature for 1 hour, the reaction mixture was diluted with ethyl acetate and washed twice with saturated sodium bicarbonate solution and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain an amide intermediate, which was used in the next reaction without further purification. MS m / z: 504.0 [M+1] + .
[0201] Acetic acid (10 mL) was added to the above amide intermediate. After stirring at 80°C for 1 hour, the solvent was removed under reduced pressure. The crude product was purified by C18 column chromatography using elution with 0-100% ACN / water containing 10 mM ammonium acetate to obtain the title compound (0.4 g, 77%). 1H NMR(DMSO-d6)δ:12.59(br MS m / z:486.1[M+1] + .
[0202] Step 4.5-[1H-benzimidazole-2-yl-(5-fluoro-2-methoxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6,7-dihydrothieno[3,2-c]pyridine-4-one [ka] A mixture of 5-[1H-benzimidazole-2-yl-(5-fluoro-2-methoxyphenyl)methyl]-2-bromo-6,7-dihydrothieno[3,2-c]pyridine-4-one (0.200 g, 0.411 mmol), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine (0.148 g, 0.493 mmol), Pd(dppf)Cl2 (0.030 g, 0.041 mmol), and sodium carbonate (0.130 g, 1.23 mmol) in dioxane / water (9:1, 6 mL) was heated under nitrogen at 100 °C for 2 hours. After cooling, the reaction mixture was filtered, the filtrate was concentrated, and the resulting solution was purified by silica gel flash chromatography using elution with 0-15% methanol in dichloromethane to obtain the title compound (0.2 g, 84%). 1 H NMR(400MHz,DMSO-d6)δ:12.56(s,1H),7.56-7.64(m,4H),7.41-7.49(m,1H),7.10-7.31(m,7H),6.83-6.90(m,1H),3.66-3 .82(m,4H),3.40-3.46(m,1H),2.90-3.17(m,4H),2.52-2.56(m,1H),2.30(s,3H),2.04-2.21(m,2H),1.64-1.81(m,4H).MS m / z:581.5[M+1] + .
[0203] Step 5.5-[1H-benzimidazole-2-yl-(5-fluoro-2-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6,7-dihydrothieno[3,2-c]pyridine-4-one dihydrochloride [ka] To a solution of 5-[1H-benzimidazole-2-yl-(5-fluoro-2-methoxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6,7-dihydrothieno[3,2-c]pyridine-4-one (0.200 g, 0.344 mmol) in 10 mL of dichloromethane at 0°C, boron tribromide (0.859 g, 3.43 mmol) was added. After stirring at room temperature for 2 hours, the reaction mixture was diluted with dichloromethane and poured into ice water. The aqueous phase was extracted three times with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by reverse-phase HPLC eluting with 0-100% ACN / water (0.05% HCl modifier) to obtain the title compound (0.107 g, 55%). 1 H NMR(400MHz,DMSO-d6)δ:10.06-10.82(m,2H),7.69-7.78(m,2H),7.60-7.67(m,3H),7.39-7.53(m,2H),7.29(d,2H), MS m / z:567.5[M+1] + .
[0204] The following examples were prepared from methyl 2-bromo-2-(5-fluoro-2-methoxyphenyl)acetate and the corresponding bicyclic starting material by the same method as in Example 4. [Table 7-1] [Table 7-2]
[0205] Example 5: Preparation of 6-[(R)-1H-benzimidazole-2-yl-(5-fluoro-2-hydroxy-phenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]thieno[2,3-c]pyridine-7-one and 6-[(S)-1H-benzimidazole-2-yl-(5-fluoro-2-hydroxy-phenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]thieno[2,3-c]pyridine-7-one (015 and 016) [ka] 6-[1H-benzimidazole-2-yl-(5-fluoro-2-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]thieno[2,3-c]pyridine-7-one dihydrochloride (009, 0.300 g, 0.470 mmol) was purified by preparative SFC at 40°C using a Chiral Technologies Chiralpak IA (5 micron 250 × 10 mm) column eluted at 10 MPa with 50% (0.3% TEA in MeOH) / 50% CO2 to separate the enantiomers. The absolute configuration of the chiral center for each isolated enantiomer is unknown. First elution peak (015) (93 mg, 35% yield, 99.6:0.4er), [α] 20 D +58.2 (c=0.91, MeOH), 1 H NMR(DMSO-d6)δ:12.79(br s,1H),10.01(br s,1H),7.70-7.80(m,3H),7.65(s,1H),7.46-7.61(m,2H),7.32-7.40(m,3H),7.16-7.25(m,2H),7.05-7.14(m,1H),6.85-6.93 MS m / z:565.2[M+1]+ .Second elution peak (016) (95 mg, 36% yield, 99.4:0.6er), [α] 20 D -52.5 (c=0.92, MeOH), 1 H NMR(DMSO-d6)δ:12.79(br s,1H),10.02(br s,1H),7.70-7.78(m,3H),7.65(s,1H),7.44-7.60(m,2H),7.33-7.40(m,3H),7.15-7.24(m,2H),7.06-7.13(m,1H),6.86-6.93 MS m / z:565.2[M+1] + .
[0206] Example 6: 5-[1H-benzimidazole-2-yl-(5-fluoro-2-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6H-thieno[2,3-c]pyrrole-4-one dihydrochloride (013) [ka] Step 1.2-Bromo-4-fluoro-1-(methoxymethoxy)benzene [ka] To a solution of 2-bromo-4-fluorophenol (100 g, 523 mmol) in THF (1 L), sodium hydride (23.0 g, 575 mmol, 60% in mineral oil) was added at 0°C for 4 hours, followed by the addition of methoxymethyl chloride (44.9 mL, 601 mmol). After stirring at room temperature for 10 hours, the reaction mixture was quenched with water and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluted with 1-10% ethyl acetate in petroleum ether to obtain the title compound (80 g, 65%).1 H NMR(400MHz, CDCl3)δ:7.30(dd,1H),7.12(dd,1H),6.97(m,1H),5.07-5.24(m,2H),3.46-3.62(m,3H).
[0207] Step 2.2-[5-fluoro-2-(methoxymethoxy)phenyl]-2-oxoethyl acetate [ka] To a solution of 2-bromo-4-fluoro-1-(methoxymethoxy)benzene (80.0 g, 340 mmol) in THF (1 L) at -78°C, n-butyllithium (2.5 M in hexane, 142 mL, 357 mmol) was added dropwise. After stirring at -78°C for 1 hour, the reaction mixture was cannulated into a pre-cooled (-78°C) solution of diethyl oxalate (74.4 g, 510 mmol) in THF (500 mL). After the addition was complete, the reaction mixture was warmed to room temperature. The reaction mixture was quenched with water and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with 10% ethyl acetate in petroleum ether to obtain the title compound (70 g, 80%). 1 H NMR(400MHz,CDCl3)δ:7.57(dd,1H),7.26-7.31(m,1H),7.18-7.23(m,1H),5.15(s,2H),4.37-4.43(m,2H),3.46-3.50(m,3H),1.35-1.41(m,3H).
[0208] Step 3. Ethyl-2-[5-fluoro-2-(methoxymethoxy)phenyl]-2-hydroxyiminoacetate [ka] To a solution of hydroxylamine hydrochloride (37.9 g, 546 mmol) in ethanol (500 mL), 2-[5-fluoro-2-(methoxymethoxy)phenyl]-2-oxo-ethyl acetate (70.0 g, 273 mmol) and sodium acetate (44.7 g, 132 mmol) were added. After stirring at 80°C for 2.5 hours, the solvent was removed under reduced pressure, and the resulting residue was partitioned into water and dichloromethane. The aqueous phase was extracted with additional dichloromethane. The combined organic extract was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (68 g, 92%). 1 H NMR(400MHz,CDCl3)δ:9.76(br s,1H),7.17-7.23(m,1H),7.07-7.14(m,2H),5.10(s,2H),4.31-4.39(m,2H),3.44-3.48(m,3H),1.35-1.40(m,3H).
[0209] Step 4. 2-amino-2-[5-fluoro-2-(methoxymethoxy)phenyl]ethyl acetate [ka] To a solution of Raney Ni (1.46 g, 25.0 mmol) in EtOH / THF (650 mL, 4 / 1), ethyl-2-[5-fluoro-2-(methoxymethoxy)phenyl]-2-hydroxyimino acetate (34.0 g, 125 mmol) was added. The flask was emptied, refilled with hydrogen, and the reaction mixture was stirred at 70°C under a hydrogen atmosphere (50 psi) for 24 hours. The reaction mixture was filtered through a Celite pad and washed several times with ethanol. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography eluted with 33% ethyl acetate in petroleum ether to obtain the title compound (30.6 g, 48%). 1 H NMR(400MHz,DMSO-d6)δ:7.23(dd,1H),7.04-7.08(m,2H),5.14-5.18(m,2H),4.66(s,1H),3.92-4.12(m,2H),3.37(s,3H),1.06-1.22(m,3H).
[0210] Step 5. 5-Bromo-2-[[[2-Ethoxy-1-[5-Fluoro-2-(methoxymethoxy)phenyl]-2-oxo-ethyl]amino]methyl]thiophene-3-carboxylate methyl [ka] To a solution of 2-amino-2-[5-fluoro-2-(methoxymethoxy)phenyl]ethyl acetate (0.409 g, 1.59 mmol) and 5-bromo-2-(bromomethyl)thiophene-3-carboxylate methyl (0.500 g, 1.59 mmol) in DMF (15 mL), DIPEA (0.789 mL, 4.77 mmol) was added. The reaction mixture was heated at 80°C for 3 hours. After cooling to room temperature, the reaction mixture was poured into water and extracted three times with ethyl acetate. The combined organic extracts were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with 0-25% ethyl acetate in petroleum ether to obtain the title compound (0.32 g, 41%). MS m / z: 491.8 [M+1]
[0211] Step 6.2-(2-bromo-4-oxo-6H-thieno[2,3-c]pyrrole-5-yl)-2-[5-fluoro-2-(methoxymethoxy)-phenyl]ethyl acetate [ka] To a solution of methyl 5-bromo-2-[[[2-ethoxy-1-[5-fluoro-2-(methoxymethoxy)phenyl]-2-oxo-ethyl]amino]methyl]thiophene-3-carboxylate (0.610 g, 1.24 mmol) in toluene (20 mL), trimethylaluminum (2 M, 1.86 mL, 3.72 mmol) in toluene was added. The reaction mixture was heated at 110 °C for 4 hours. After cooling to room temperature, the reaction mixture was poured into a saturated ammonium chloride solution and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluted with 1-10% ethyl acetate in petroleum ether to obtain the title compound (0.13 g, 23%). MS m / z: 458.0 [M+1] + .
[0212] Step 7.2-(2-bromo-4-oxo-6H-thieno[2,3-c]pyrrole-5-yl)-2-[5-fluoro-2-(methoxymethoxy)-phenyl]acetic acid [ka] To a solution of 2-(2-bromo-4-oxo-6H-thieno[2,3-c]pyrrole-5-yl)-2-[5-fluoro-2-(methoxymethoxy)phenyl]ethyl acetate (0.130 g, 0.283 mmol) in THF / water (8 mL, 1 / 1), lithium hydroxide (0.021 g, 0.849 mmol) was added. After stirring at room temperature for 2 hours, the solvent was removed under reduced pressure, and the resulting residue was adjusted to pH 4 with HCl (1 M). The resulting solid was collected by filtration and washed with water to obtain the title compound (0.09 g, 74%). MS m / z: 429.9 [M+1] + .
[0213] Step 8.5-[1H-benzimidazole-2-yl-[5-fluoro-2-(methoxymethoxy)phenyl]methyl]-2-bromo-6H-thieno[2,3-c]pyrrole-4-one [ka] To a solution of 2-(2-bromo-4-oxo-6H-thieno[2,3-c]pyrrole-5-yl)-2-[5-fluoro-2-(methoxymethoxy)phenyl]acetic acid (0.090 g, 0.209 mmol), 1,2-diaminobenzene (0.027 g, 0.250 mmol), and HATU (0.103 g, 0.271 mmol) in DMF (3 mL), DIPEA (0.103 mL, 0.627 mmol) was added. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate and washed twice with saturated sodium bicarbonate solution and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain an amide intermediate, which was used in the next reaction without further purification. MS m / z: 519.9 [M+1] + .
[0214] Acetic acid (8 mL) was added to the above amide intermediate. After stirring at 80°C for 1 hour, the solvent was removed under reduced pressure. The crude product was purified by C18 column chromatography using elution with 0-100% ACN / water containing 10 mM ammonium acetate to obtain the title compound (0.07 g, 73%). MS m / z: 502.0 [M+1] + .
[0215] Step 9.5-[1H-benzimidazole-2-yl-[5-fluoro-2-(methoxymethoxy)phenyl]methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6H-thieno[2,3-c]pyrrole-4-one [ka] A mixture of 5-[1H-benzimidazole-2-yl-[5-fluoro-2-(methoxymethoxy)phenyl]methyl]-2-bromo-6H-thieno[2,3-c]pyrrole-4-one (0.070 g, 0.139 mmol), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine (0.050 g, 0.166 mmol), Pd(dppf)Cl2 (0.010 g, 0.014 mmol), and sodium carbonate (0.046 g, 0.416 mmol) in dioxane / water (4:1, 3 mL) was heated under nitrogen at 100 °C for 4 hours. After cooling, the reaction mixture was filtered, the filtrate was concentrated, and the resulting solution was purified by silica gel flash chromatography using elution with 0-10% methanol in dichloromethane to obtain the title compound (0.05 g, 60%). MS m / z: 597.2 [M+1] + .
[0216] Step 10.5-[1H-benzimidazole-2-yl-(5-fluoro-2-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6H-thieno[2,3-c]pyrrole-4-one dihydrochloride [ka] 5-[1H-benzimidazole-2-yl-[5-fluoro-2-(methoxymethoxy)phenyl]methyl]-2-[4-(1-methyl-4-piperidyl)phenyl]-6H-thieno[2,3-c]pyrrole-4-one (0.050 g, 0.084 mmol) was added to HCl (1.25 M, 2 mL, 2.50 mmol) in methanol. After stirring at room temperature for 1 hour, the solvent was removed under reduced pressure. The crude product was purified by reverse-phase HPLC eluting with 0-100% ACN / water (0.05% HCl modifier) to obtain the title compound (0.01 g, 22%). 1H NMR (400MHz, methanol-d4) δ:7.63-7.75(m,4H),7.50-7.59(m,3H),7.37(d,2H),7.12-7.20(m,2H),7.07(s,1H),6.95- 7.01(m,1H),4.90-4.99(m,2H)4.46(d,1H),3.66-3.78(m,2H),3.12-3.24(m,2H),2.93(s,3H),1.93-2.21(m,4H);MS m / z:553.1[M+1] + .
[0217] The following examples were prepared from 2-amino-2-[5-fluoro-2-(methoxymethoxy)phenyl]ethyl acetate and the corresponding starting materials by the same method as in Example 6. [Table 8]
[0218] Example 7: Preparation of compounds 019 and 020 [ka] Step 1.2-Bromo-4-fluorothieno[2,3-c]pyridine-7(6H)-one [ka] A mixture of 2-bromothieno[2,3-c]pyridine-7(6H)-one (233 mg, 1 mmol), selectfluor (354 mg, 1 mmol), and dimethylacetamide (3 mL) was heated in a sealed microwave vial at 150°C for 15 minutes with stirring. After cooling to room temperature, the entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / water (0.038% TFA) to obtain the title compound (47 mg, 19%). NMR MS m / z: 247.8 [M+1] + .
[0219] Step 2.2-(2-bromo-4-fluoro-7-oxothieno[2,3-c]pyridine-6(7H)-yl)-2-(5-fluoro-2-(methoxymethoxy)phenyl)methyl acetate [ka] A mixture of 2-bromo-4-fluorothieno[2,3-c]pyridine-7(6H)-one (140 mg, 0.59 mmol), 2-bromo-2-(5-fluoro-2-(methoxymethoxy)phenyl)methyl acetate (218 mg, 0.71 mmol), cesium carbonate (391 mg, 1.08 mmol), and DMF (2 mL) was heated at 30°C for 6 hours. After cooling, the entire reaction mixture was purified by flash chromatography eluting with 0-50% siRNA / hexane to obtain the title compound (107 mg, 38%). 1 H NMR(500MHz,CDCl3)δ:7.34(s,1H),7.22(dd,1H),7.14(dd,1H),7.10(d,1H),7.07(dd,1H)6.93(s,1H),5.15(s,2H),3.86(s,3H),3.39(s,3H);MS m / z:475.8[M+1] + .
[0220] Step 3. 2-(4-fluoro-2-(4-(1-methylpiperidine-4-yl)phenyl)-7-oxothieno[2,3-c]pyridine-6(7H)-yl)-2-(5-fluoro-2-(methoxymethoxy)phenyl)acetic acid [ka] A mixture of 2-(2-bromo-4-fluoro-7-oxothieno[2,3-c]pyridine-6(7H)-yl)-2-(5-fluoro-2-(methoxymethoxy)phenyl)methyl acetate (100 mg, 0.21 mmol), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine (67 mg, 0.63 mmol), Na2CO3 (67 mg, 0.63 mmol), dioxane (3 mL), and water (1 mL) was degassed twice under vacuum and refilled with N2. PdCl2dppf-dcm (19 mg, 0.023 mmol) was added, and the rxn mixture was refilled with N2. The rxn mixture was heated at 95°C for 6 hours. The entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / water (0.038% TFA) to obtain the title compound (40 mg, 52%). 1 H NMR(500MHz,DMSO-d6)δ:9.46(br s,1H),7.88(m,3H),7.45(d,1H),7.39(d,2H),7.28(dd,1H),7.26(dd,1H),7.21(dd,1H),6.70(s,1H),5.23(d, MS m / z:555.1[M+1] + .
[0221] Step 4.2-(4-fluoro-2-(4-(1-methylpiperidine-4-yl)phenyl)-7-oxothieno[2,3-c]pyridine-6(7H)-yl)-2-(5-fluoro-2-hydroxyphenyl)-N-(thiazole-2-yl)acetamide(019) [ka] A mixture of 2-(4-fluoro-2-(4-(1-methylpiperidine-4-yl)phenyl)-7-oxothieno[2,3-c]pyridine-6(7H)-yl)-2-(5-fluoro-2-(methoxymethoxy)phenyl)acetic acid (20 mg, 0.036 mmol), HATU (27 mg, 0.072 mmol), 2-aminothiazole (5.4 mg, 0.072 mmol), DIEA (19 mL, 0.108 mmol), and DMF (2 mL) was stirred overnight at room temperature. The entire reaction mixture was purified by RP-HPLC with elution rates from 0 to 80%. ACN / water (0.038% TFA). MS m / z: 637.2 [M+1] + .
[0222] This material was treated with DCM:TFA (1:1, 4 mL) for 30 minutes. The solvent was removed under reduced pressure, and the entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / water (0.038% TFA) to obtain the title compound (4.8 mg, 22% in 2 steps). 1 H NMR(500MHz,DMSO-d6)δ:10.17(s,1H),9.41(br s,1H),7.90(m,3H),7.51(d,1H),7.39(d,2H),7.30(d,1H),7.21(m,1H),7.15(d,1H),6.96(dd,1H),6.9 5(s,1H),6.88(dd,1H),3.55(d,2H),3.10(m,2H),2.88(m,1H),2.83(d,3H),2.05(d,2H),1.86(m,2H);MS m / z:593.1[M+1] + .
[0223] Step 5.6-((1H-benzo[d]imidazole-2-yl)(5-fluoro-2-hydroxyphenyl)methyl)-4-fluoro-2-(4-(1-methylpiperidine-4-yl)phenyl)thieno[2,3-c]pyridine-7(6H)-one(020) [ka] A mixture of 2-(4-fluoro-2-(4-(1-methylpiperidine-4-yl)phenyl)-7-oxothieno[2,3-c]pyridine-6(7H)-yl)-2-(5-fluoro-2-(methoxymethoxy)phenyl)acetic acid (20 mg, 0.036 mmol), HATU (27 mg, 0.072 mmol), 1,2-phenylenediamine (8 mg, 0.072 mmol), DIEA (19 mL, 0.108 mmol), and DMF (2 mL) was stirred overnight at room temperature. The entire reaction mixture was purified by RP-HPLC with elution rates from 0 to 80%. ACN / water (0.038% TFA). MS m / z: 645.4 [M+1] + .
[0224] This material was dissolved in AcOH (3 mL), and the solution was heated at 100°C for 1 hour. The solvent was removed under reduced pressure. MS m / z: 627.1 [M+1] + .
[0225] This material was treated with DCM:TFA (1:1, 4 mL) for 30 minutes. The solvent was removed under reduced pressure, and the entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / water (0.038% TFA) to obtain the title compound (5.7 mg, 27% in 3 steps). 1 H NMR(500MHz,DMSO-d6)δ:10.12(brs,1H),9.46(br s,1H),7.91(s,1H),7.88(d,2H),7.61(s,1H),7.58(m,2H),7.47(d,1H),7.39(d,2H),7.24(m,2H),7.15(m,1H) MS m / z:583.2[M+1] + .
[0226] The following examples were prepared from 2-bromo-2-(5-fluoro-2-(methoxymethoxy)phenyl)acetate methyl and the corresponding starting materials by the same method as for compound 019. [Table 9]
[0227] The following examples were prepared from 2-bromo-2-(5-fluoro-2-(methoxymethoxy)phenyl)acetate methyl and the corresponding starting materials by the same method as for compound 020. [Table 10]
[0228] [ka] 2-Bromo-N-(pivaloyloxy)thiazole-5-carboxamide [ka] Oxalyl chloride (15 mL, 30 mmol, 2 M DCM solution) was added dropwise over 20 minutes to a suspension of 2-bromothiazole-5-carboxylic acid (4.2 g, 20 mmol) and anhydrous DMF (4 drops) in DCM (20 mL). The reaction mixture was stirred at room temperature for 3 days, and the solvent was removed under reduced pressure to obtain the acid chloride.
[0229] Hydroxylamine hydrochloride (1.39 g, 20 mmol) was added to a biphasic mixture of K2CO3 (5.52 g, 20 mmol) in a 2:1 mixture of siRNA (40 mL) and water (20 mL). The resulting solution was cooled to 0°C, and then crude acid chloride in siRNA (12 mL) was added dropwise over 20 minutes. The reaction mixture was warmed to room temperature to obtain a thick white suspension. After 4 hours, pivaloyl chloride (2.46 mL, 20 mmol) was added dropwise over approximately 10 minutes. After 2 hours, an additional 0.5 mL of pivaloyl chloride was added, and the reaction mixture was stirred for 16 hours. The mixture was diluted with water (125 mL) and extracted with siRNA (2 × 125 mL). The combined organic extract was washed with water and saturated brine, dried, filtered, and the residue was purified by flash chromatography with 0-35% siRNA / hexane to obtain 2.44 g (40%) of a white solid. 1H NMR(500MHz,DMSO-d6)δ:8.22(s,1H),1.28(s,9H);MS m / z:308.8[M+1] + .
[0230] 2-Bromothiazolo[5,4-c]pyridine-4(5H)-one [ka] 2-bromo-N-(pivaloyloxy)thiazole-5-carboxamide (233 mg, 1 mmol), CsCO3 (58 mg, 0.3 mmol), [Cp * A mixture of RhCl2]2 (12 mg, 0.02 mmol) was degassed and packed twice with N2. Vinyl acetate (131 mL, 1.5 mmol) was added, and the mixture was heated at 45°C for 60 hours. The entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / water (0.038% TFA) to obtain the title compound (16 mg, 7%). MS m / z: 232.8 [M+1] + .
[0231] [ka] 2-(5-fluoro-2-methoxyphenyl)methyl acetate [ka] Thionyl chloride (5.8 mL, 81.3 mmol) was added dropwise to a solution of 2-(5-fluoro-2-methoxyphenyl)acetic acid (5.0 g, 27.1 mmol) in MeOH (3 mL) over 15 minutes at 0°C. The mixture was heated at 60°C for 16 hours, and the solvent was removed under reduced pressure. Depositphotos (100 mL) and saturated brine (100 mL) were added, and the pH was adjusted to 9 with saturated NaHCO3 solution. The organic layer was washed with brine, dried, and concentrated to obtain the title compound (5.13 g, 95%), which was used without further purification. 1H NMR(500MHz,CDCl3)δ:6.96(m,2H),6.81(m,1H),3.81(s,3H),3.72(s,3H),3.63(s,2H).
[0232] 2-(5-fluoro-2-hydroxyphenyl)methyl acetate [ka] BBr3 (77 mL, 1 M in DCM) was added dropwise over 45 minutes at -78°C to a solution of methyl 2-(5-fluoro-2-methoxyphenyl)acetate in DCM (100 mL), and the mixture was stirred for 1 hour. The reaction mixture was quenched with water (50 mL). DCM (100 mL) and water (50 mL) were added, and the pH was adjusted to 8 with saturated NaHCO3 solution. The organic layer was washed with brine, dried, and concentrated to obtain the title compound (4.38 g, 92%), which was used without further purification. 1 H NMR(500MHz,CDCl3)δ:7.16(s,1H),6.90(dd,1H),6.85(dd,1H),3.79(s,3H),3.66(s,2H),3.67(s,2H).
[0233] 2-(5-fluoro-2-(methoxymethoxy)phenyl)methyl acetate [ka] Diisopropylethylamine (12.4 mL, 71.4 mmol) and chloromethyl methyl ether (4.52 mL, 59.5 mmol) 2-(5-fluoro-2-hydroxyphenyl)acetate methyl was added to a solution of 2-(5-fluoro-2-hydroxyphenyl)acetate methyl (4.38 g, 23.8 mmol) in DCM (150 mL). The reaction mixture was stirred for 20 hours. DCM (100 mL) and brine (100 mL) were added, the organic layer was washed with brine and dried (Na2SO4), and the residue was purified by silica chromatography (0-20% HCl in Hex) to obtain the title compound (4.78 g, 88%). 1H NMR(500MHz,CDCl3)δ:7.07(dd,1H),6.96(dd,1H),6.94(m,1H),5.16(s,2H),3.72(s,3H),3.66(s,2H),3.48(s,3H).
[0234] 2-Bromo-2-(5-Fluoro-2-(methoxymethoxy)phenyl)methyl acetate [ka] NBS (3.05 g, 17.1 mmol) and benzoyl peroxide (396 mg, 1.63 mmol) were added to a solution of methyl 2-(5-fluoro-2-(methoxymethoxy)phenyl)acetate (3.72 g, 16.3 mmol) in CCl4 (80 mL). The reaction mixture was stirred at 80°C for 20 hours. RINKAN (150 mL) and brine (100 mL) were added, the organic layer was washed with brine, dried (Na2SO4), and the residue was purified by silica chromatography (0-10% RINKAN in Hex) to obtain the title compound (3.59 g, 72%). 1 H NMR(500MHz,CDCl3)δ:7.41(dd,1H),7.09(dd,1H),7.02(m,1H),5.85(s,1H),5.22(d,1H),5.21(d,1H),3.82(s,3H),3.51(s,3H).
[0235] Example 8: Preparation of 6-((1H-benzo[d]imidazole-2-yl)(5-fluoro-2-hydroxyphenyl)methyl-d)-2-(4-(1-methylpiperidine-4-yl)phenyl)thieno[2,3-c]pyridine-7(6H)-one(024) [ka] A solution of 6-((1H-benzo[d]imidazole-2-yl)(5-fluoro-2-hydroxyphenyl)methyl)-2-(4-(1-methylpiperidine-4-yl)phenyl)thieno[2,3-c]pyridine-7(6H)-one (009, 20 mg, 0.035 mmol), deuterium oxide (350 mL, 19.3 mmol), DIEA (38 mL, 6.3 mmol), and anhydrous THF (1 mL) was stirred at 70°C for 60 hours. The entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / H2O (0.038% TFA modifier) to obtain the title compound (12 mg, 62%). NMR (500 MHz, DMSO-d6)δ: 1 H 10.06(br s,1H),9.39(br s,1H),7.80(d,2H),7.77(s,1H),7.57(m,2H),7.38(m,3H),7.24(m,2H),7.13(m,1H),6.92(dd,1H),6.78(d,1H), 6.69(dd,1H),3.54(m,2H),3.09(m,2H),2.87(m,1H),2.84(d,3H),2.06(d,2H),1.85(m,2H).MS,m / z566.15,[M+1] + .
[0236] Example 9: Preparation of 6-((1H-indole-2-yl)(phenyl)methyl)-2-(4-(1-methylpiperidine-4-yl)phenyl)thieno[2,3-c]pyridine-7(6H)-one(025) [ka] Step 1.2-Formyl-1H-indole-1-carboxylate tert-butyl [ka] A solution of triethylamine (0.6 mL, 4.0 mmol), DMAP (41 mg, 0.34 mmol), 1H-indole-2-carbaldehyde (0.5 g, 3.4 mmol), and THF (15 mL) was cooled to 0°C. Di-tert-butyl dicarbonate (0.87 g, 4.0 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure, and the residue was divided into water (30 mL) and ethyl acetate (30 mL). The aqueous solutions were then extracted with ethyl acetate, and the combined organic layers were dried over (Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified by silica chromatography (0-30% ethyl acetate / hexane) to obtain the title compound (570 mg, 68%). 1 H NMR(500MHz,CDCl3)δ:10.46(s,1H),8.19(d,1H),7.70(d,1H),7.51(t,1H),7.46(s,1H),7.33(t,1H),1.74(s,9H).
[0237] Step 2. 2-(hydroxy(phenyl)methyl)-1H-indole-1-carboxylate tert-butyl [ka] Phenylenidummagnesium bromide (1M in THF, 2.79 mL, 2.79 mmol) was added dropwise to a solution of tert-butyl 2-formyl-1H-indole-1-carboxylate (0.57 g, 2.32 mmol) in anhydrous THF at 0°C. The reaction mixture was stirred at 0°C for 30 minutes and quenched with saturated aqueous solution NH4Cl (10 mL). The mixture was extracted with siRNA (2 × 20 mL), dried to (Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified by silica chromatography (0-30% siRNA / hexane) to obtain the title compound (500 mg, 67%). 1 H NMR(500MHz,CDCl3)δ:7.99(d,1H),7.45(d,3H),7.39(m,2H),7.34(m,1H),7.31(m,1H),7.23(t,1H),6.23(s,1H),6.21(d,1H),4.71(br d,1H),1.67(s,9H).
[0238] Step 3.2-(((methylsulfonyl)oxy)(phenyl)methyl)-1H-indole-1-carboxylate tert-butyl [ka] Mesil chloride (143 mL, 1.86 mmol) was added dropwise at 0°C to a solution of 2-(hydroxy(phenyl)methyl)-1H-indole-1-carboxylate tert-butyl (300 mg, 0.93 mmol), DIEA (647 mL, 3.72 mmol), and anhydrous DCM (10 mL). The reaction mixture was stirred at 0°C for 15 minutes and then at room temperature for 1 hour, after which it was diluted with DCM (10 mL) and quenched with ice water (20 mL). The organic layer was collected, dried (Na2SO4), filtered, and concentrated under reduced pressure to obtain the crude mesilate, which was used in the next step without further purification.
[0239] Step 4.6-((1H-indole-2-yl)(phenyl)methyl)-2-bromothieno[2,3-c]pyridine-7(6H)-one [ka] The materials from Step 3 were dissolved in DMF (3 mL) and added dropwise to a suspension of 2-bromothieno[2,3-c]pyridine-7(6H)-one (193 mg, 0.81 mmol) and Cs2CO3 (673 mg, 1.86 mmol) in DMF (8 mL). The reaction mixture was heated at 36 °C for 6 hours. After cooling, the reaction mixture was poured into ice water (20 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic extracts were washed with saturated brine (20 mL), dried, filtered, and concentrated under reduced pressure. The residue was purified by silica chromatography (0-30% ethyl acetate / hexane) to obtain the title compound (120 mg, 30% in 2 steps). 1 H NMR(500MHz,CDCl3)δ:9.81(s,1H),7.62(s,1H),7.58(d,1H),7.39(m,4H),7 .33(m,2H),7.23(m,2H),7.13(t,1H),7.09(s,1H),6.50(d,1H),6.31(s,1H),
[0240] Step 4.6-((1H-indole-2-yl)(phenyl)methyl)-2-(4-(1-methylpiperidine-4-yl)phenyl)thieno[2,3-c]pyridine-7(6H)-one [ka] A mixture of 6-((1H-indole-2-yl)(phenyl)methyl)-2-bromothieno[2,3-c]pyridine-7(6H)-one (120 mg, 0.27 mmol), 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine (90 mg, 0.3 mmol), Na2CO3 (86 mg, 0.81 mmol), dioxane (3 mL), and water (1 mL) was degassed and packed twice with N2. PdCl2dppf-dcm (44 mg, 0.054 mmol) was added, the mixture was degassed, and packed with N2. The reaction mixture was heated at 95°C for 20 minutes. After cooling, the entire reaction mixture was purified by RP-HPLC elution with 0-80% ACN / H2O (0.038% TFA) to obtain the title compound (54 mg, 38%). NMR (500 MHz, DMSO-d6) δ: 1 H 11.42(s,1H),9.43(br s,1H),7.80(d,2H),7.77(s,1H),7.50(d,2H),7.44(m,2H),7.38(m,3H),7.31(m,4H),7.11(t,1H),7.00(t,1H) ),6.78(d,1H),6.09(s,1H),3.54(d,2H),3.10(m,2H),2.87(m,1H),2.84(d,3H),2.06(d,2H),1.86(m,2H).MS m / z:530.25[M+1] + .
[0241] Example 10: HTRF-based EGFR biochemical assay EGFR biochemical activity was measured using a homogeneous time-resolved fluorescence (HTRF) assay (Cisbio). Inhibitors and DMSO normalizers were first dispensed into empty black low-volume 384-well plates (Corning) using a D300 digital liquid dispenser (HP). All reactions were carried out at room temperature, and solutions were added to the plates using a Multidrop Combi reagent dispenser (ThermoFisher). The reaction mixture (final volume 10 μL) contained 1 μM tyrosine kinase peptide-biotin substrate and mutant EGFR in reaction buffer (50 mM HEPES pH 7.0, 5 mM MgCl2, 1 mM MnCl2, 0.01% BSA, 2 mM TCEP, 0.1 mM NaVO4). Enzyme concentrations were adjusted to suit various kinase activities (L858R 0.1 nM, L858R / T790M 0.02 nM). The enzyme reaction solution (2× concentration, 5 μL) was added to a 384-well plate containing the compound and incubated for 30 minutes. The enzyme reaction was initiated with the addition of 5 μL of ATP to a final concentration of 100 μM and allowed to react for 20 minutes. The reaction was quenched with the addition of 10 μL of phosphotyrosine antibody-europium(III) cryptotate (1:180 volume ratio) and streptavidin-XL665 (46.7 nM) in EDTA-containing detection buffer, then incubated at room temperature for 1 hour and read using a PHERAstar plate reader (excitation = 337 nm, emission = 620 nm and 665 nm). IC 50 The values were determined in three ways using nonlinear least-squares curves fitted to GraphPad Prism 7.0d (either an 11-point curve from 1.0 μM to 0.130 nM, or a 23-point curve from 1.0 μM to 0.130 pM). The obtained data are shown in Table 4 below. [Table 11]
[0242] Example 11: Ba / F3 cell proliferation model EGFR mutants L858R and L858R / T790M Ba / F3 cells have been previously described (Zhou, W., et al. Nature 462, 2009, 1070-1074). All cell lines were maintained in RPMI 1640 (Cellgro; Mediatech Inc., Herndon, CA) supplemented with 10% FBS, 100 units / mL penicillin, and 100 units / mL streptomycin. The EGFR I941R mutant was introduced via site-directed mutagenesis using the Quick Change site-directed mutagenesis kit (Stratagene; La Jolla, CA) according to the manufacturer's instructions. All constructs were confirmed by DNA sequencing. The constructs were shuttled to the retroviral vector JP1540 using the Cre-recombination system (Agilent Technologies, Santa Clara, CA). Next, Ba / F3 cells were infected with retrovirus according to the standard protocol, as previously described (Zhou, et al, Nature 2009). Stable clones were obtained by selection in puromycin (2 μg / ml).
[0243] Cell proliferation and inhibition were evaluated by the Cell Titer Glo assay (Promega, Madison, WI), performed according to the manufacturer's instructions. The Cell Titer Glo assay is a luminescence-based method used to determine the number of viable cells based on the quantification of ATP present, which is directly proportional to the amount of metabolically active cells present. Ba / F3 cells with different EGFR genotypes were exposed to the compound for 72 hours, either as a monotherapy or in combination with 1 μg / mL cetuximab, and the number of cells used per experiment was determined empirically as previously established (Zhou, et al., Nature 2009). All experimental points were set up in three different ways in a 384-well plate, and all experiments were repeated at least three times. Luminescence signals were detected using a spectrometer, and the data were graphed using GraphPad Prism version 5.0 for Windows (GraphPad Software; www.graphpad.com). Curves were fitted using a nonlinear regression model with sigmoid dose response. The results of this assay for the compounds disclosed herein are shown in Table 5 below. [Table 12]
[0244] The subject matter disclosed should not be limited in scope by the specific embodiments and examples described herein. In fact, various modifications of the disclosure other than those described will be apparent to those skilled in the art from the above description and the accompanying drawings. These modifications shall be included in the scope of the accompanying "Claims".
[0245] All references cited herein (e.g., publications, patents, or patent applications) are incorporated herein by reference in the same way as each individual reference (e.g., publications, patents, or patent applications) is specifically and individually indicated to be incorporated by reference in its entirety for any purpose. Other embodiments are included in the following claims.
Claims
1. Compound of formula X: 【Chemistry 1】 or a pharmaceutically acceptable salt thereof During the ceremony, 【Chemistry 2】 However, it represents a single bond or a double bond. A and A' are CH2, Alternatively, A is absent, W is C, Z is selected from the group consisting of S, N, or CH. X is S or CH, Y is CR 3 And, However, when Z is S, X is CH, and when X is S, Z is CH or N. R 1 However, C(O)NHR 9 , and selected from the group consisting of 5-10 member heteroaryls, R 2 However, selected from the group consisting of 6- to 10-membered aryls arbitrarily substituted with 1, 2, or 3 R6s, R 3 but, 【Transformation 5】 And, R 6 However, in each occurrence, a selection is made independently from the group consisting of halogens and OH. R 7 is C 1 to C 6 alkyl. R 9 The compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of 5 to 10-membered heteroaryls.
2. The compound of formula X is the compound of formula Xa: 【Transformation 3】 or a pharmaceutically acceptable salt thereof, Compound of formula Xb: 【Chemistry 4】 The compound according to claim 1, or a pharmaceutically acceptable salt thereof.
3. R 2 However, 1, 2, or 3 R 6 The compound according to claim 1 or 2, wherein the phenyl is optionally substituted with phenyl.
4. R 7 However, C 1 ~C 3 A compound according to any one of claims 1 to 3, wherein it is alkyl.
5. R 6 The compound according to any one of claims 1 to 4, wherein each occurrence is independently hydroxyl or fluoro.
6. R 1 The compound according to any one of claims 1 to 5, selected from the group consisting of benzimidazole, imidazopyridine, indole, triazole, pyrazole, imidazole, pyridinylamide, and thiazolylamide.
7. R 1 but, 【Transformation 6】 A compound according to claim 6, selected from the group consisting of the following. 【Request Item 8】 【Chemistry 7】 A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the following.
9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
10. The pharmaceutical composition according to claim 9, wherein the composition further comprises a second activator.
11. The pharmaceutical composition according to claim 10, wherein the second activator prevents EGFR dimer formation in the target and is optionally selected from the group consisting of cetuximab, trastuzumab, and panitumumab.
12. The pharmaceutical composition according to claim 10, wherein the second activator is an ATP-competitive EGFR inhibitor, and the ATP-competitive EGFR inhibitor is optionally selected from the group consisting of osimertinib, gefitinib, and erlotinib.
13. Use of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, or a composition according to any one of claims 9 to 12, in the manufacture of a cancer treatment drug for a person in need of cancer treatment.
14. The use according to claim 13, wherein the cancer is selected from the group consisting of lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, and prostate cancer.
15. The use according to claim 14, wherein the lung cancer is non-small cell lung cancer (NSCLC).
16. Use of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, or a composition according to any one of claims 9 to 12, in the manufacture of an EGFR kinase inhibitor for subjects requiring inhibition of EGFR kinase.
Citation Information
Patent Citations
New substituted dihydropyrazolotriazinone compounds, useful for treating bacterial diseases / infections
DE102005021963A1
Pyrimidinone derivatives and methods of use thereof
JP2010524940A
egfr inhibitors and methods of use thereof
JP2018522879A
compounds
WO2020002487A1
Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer
WO2020036386A1
